Marizyme (MRZM) S-1 14 Feb 22 IPO registration Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2021
Document Information [Line Items]
Document Type	S-1
Amendment Flag	false
Entity Registrant Name	MARIZYME, INC.
Entity Central Index Key	0001413754
Entity Tax Identification Number	82-5464863
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	555 Heritage Drive
Entity Address, Address Line Two	Suite 205
Entity Address, City or Town	Jupiter
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33458
City Area Code	925
Local Phone Number	400-3123
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Business Contact [Member]
Document Information [Line Items]
Entity Address, Address Line One	555 Heritage Drive
Entity Address, Address Line Two	Suite 205
Entity Address, City or Town	Jupiter
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33458
City Area Code	925
Local Phone Number	400-3123

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash	$ 16,673	$ 2,902,762	$ 90
Accounts receivable	96,291	40,585
Prepaid expense	35,000	106,390
Inventory	15,390	56,340
Total current assets	163,354	3,106,077	90
Non-current
Fixed assets, net	1,273	7,122
Operating lease right-of-use assets	1,163,159	1,317,830
Intangible assets, net	46,385,121	42,278,211	28,613,000
Prepaid royalties, non-current	340,969	344,321
Deposits	30,000	30,000
Goodwill	5,416,000
Total non-current assets	53,336,522	43,977,484
Total assets	53,499,876	47,083,561	28,613,090
Current liabilities
Accounts payable and accrued expenses	1,396,945	478,103	270,218
Due to related parties	638,530
Operating lease obligations, current portion	260,106	243,292
Total current liabilities	2,295,581	721,395	270,218
Non-current liabilities
Operating lease obligations, non-current portion	941,732	1,074,538
Convertible notes, net of debt discount	179,457
Derivative liabilities	391,648
Contingent liabilities	9,454,000
Total non-current liabilities	10,966,837	1,074,538
Total liabilities	13,262,418	1,795,933	270,218
Commitments and contingencies (see Note 6)
Stockholders’ equity
Preferred stock, $0.001 par value, 25,000,000 shares authorized, 0 shares issued and outstanding as of December 31, 2020 and 2019
Common stock, par value $0.001, 75,000,000 shares authorized, 35,928,188 and 19,858,939 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively	35,928	35,928	19,859
Additional paid in capital	82,509,957	82,077,334	59,303,594
Accumulated deficit	(42,308,427)	(36,825,634)	(30,980,581)
Total stockholders’ equity	40,237,458	45,287,628	28,342,872
Total liabilities and stockholders’ equity	$ 53,499,876	$ 47,083,561	$ 28,613,090

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000	25,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares outstanding	0	0	0
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	75,000,000	75,000,000	75,000,000
Common stock, shares issued	35,928,188	35,928,188	19,858,939
Common stock, shares outstanding	35,928,188	35,928,188	19,858,939

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenue	$ 37,215	$ 124,985	$ 271,952	$ 124,985	$ 197,136
Operating expenses
Direct costs of revenue	18,356	25,714	168,419	25,714	58,292
Professional fees	556,254	170,753	1,808,093	494,295	1,543,817	281,856
Salary expenses	617,826	433,318	2,478,357	433,318	1,153,978
Stock-based compensation	64,074	1,107,085	626,449	1,674,200
Stock-based compensation and stock issued for services					1,833,292	698,587
Depreciation and amortization					591,458
Other general and administrative expenses	536,483	453,158	1,071,017	468,782	815,902	77,596
Total operating expenses	1,792,993	2,190,028	6,152,335	3,096,309	5,996,739	1,058,039
Loss from operations	(1,755,778)	(2,065,043)	(5,880,383)	(2,971,324)	(5,799,603)	(1,058,039)
Other expense
Interest expense					(45,450)
Interest and accretion expenses	(70,221)		(74,410)
Change in fair value of contingent liabilities	194,000		472,000
Total other expense	123,779		397,590		(45,450)
Net loss	$ (1,631,999)	$ (2,065,043)	$ (5,482,793)	$ (2,971,324)	$ (5,845,053)	$ (1,058,039)
Loss per share – basic and diluted	$ (0.05)	$ (0.07)	$ (0.15)	$ (0.13)	$ (0.22)	$ (0.05)
Weighted average number of shares of common stock – basic and diluted	35,928,188	29,288,226	35,928,188	23,161,329	26,373,982	19,805,959

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Professional fees related parties	$ 90,000	$ 90,000	$ 270,000	$ 90,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
Beginning balance, shares at Dec. 31, 2018		19,740,302
Beginning balance, value at Dec. 31, 2018		$ 19,740	$ 58,480,126		$ (29,922,542)	$ 28,577,324
Forgiveness of debt for services			90,000			90,000
Issuance of shares		$ 119	124,881			$ 125,000
Issuance of shares, shares		118,637
Exercise of options for common stock, shares
Stock-based compensation expense			608,587			$ 608,587
Net loss					(1,058,039)	(1,058,039)
Ending balance, value at Dec. 31, 2019		$ 19,859	59,319,594	$ (16,000)	(30,980,581)	28,342,872
Ending balance, shares at Dec. 31, 2019		19,858,939
Ending balance, value at Dec. 31, 2019		$ 19,859	59,303,594		(30,980,581)	28,342,872
Issuance of common stock for services		$ 125	124,875			125,000
Issuance of common stock for services, shares		125,000
Stock-based compensation expense			221,058			221,058
Net loss					(471,370)	(471,370)
Ending balance, value at Mar. 31, 2020		$ 19,984	59,665,527	(16,000)	(31,451,951)	28,217,560
Ending balance, shares at Mar. 31, 2020		19,983,939
Beginning balance, value at Dec. 31, 2019		$ 19,859	59,319,594	(16,000)	(30,980,581)	28,342,872
Beginning balance, shares at Dec. 31, 2019		19,858,939
Beginning balance, value at Dec. 31, 2019		$ 19,859	59,303,594		(30,980,581)	28,342,872
Net loss						(2,971,324)
Ending balance, value at Sep. 30, 2020		$ 35,888	81,946,582	(16,000)	(33,951,905)	48,014,565
Ending balance, shares at Sep. 30, 2020		35,888,188
Beginning balance, value at Dec. 31, 2019		$ 19,859	59,319,594	(16,000)	(30,980,581)	28,342,872
Beginning balance, shares at Dec. 31, 2019		19,858,939
Beginning balance, value at Dec. 31, 2019		$ 19,859	59,303,594		(30,980,581)	28,342,872
Issuance of common stock in connection with business combination		$ 10,000	12,490,000			12,500,000
Issuance of common stock in connection with business combination, shares		10,000,000
Issuance of warrants for services			253,749			253,749
Issuance of common stock in lieu of payables		$ 254	261,199			$ 261,453
Issuance of common stock in lieu of payables, shares		254,057
Exercise of options for common stock, shares						254,057
Issuance of common stock for services		$ 215	237,285			$ 237,500
Issuance of common stock for services, shares		215,000
Issuance of common stock for cash, net of offering costs		$ 5,600	6,269,564			6,275,164
Issuance of shares and Sale of common stock for cash, net of offering costs, shares		5,600,192
Stock-based compensation expense			1,329,643			1,329,643
Issuance of warrants in connection with business combination			1,932,300			1,932,300
Net loss					(5,845,053)	(5,845,053)
Ending balance, value at Dec. 31, 2020		$ 35,928	82,077,334		(36,825,634)	45,287,628
Ending balance, shares at Dec. 31, 2020		35,928,188
Ending balance, value at Dec. 31, 2020		$ 35,928	82,077,334		(36,825,634)	45,287,628
Beginning balance, value at Mar. 31, 2020		$ 19,984	59,665,527	(16,000)	(31,451,951)	28,217,560
Beginning balance, shares at Mar. 31, 2020		19,983,939
Issuance of common stock in lieu of payables		$ 195	184,665			184,860
Issuance of common stock in lieu of payables, shares		195,000
Exercise of options for common stock		$ 5	5,045			5,050
Exercise of options for common stock, shares		5,000
Stock-based compensation expense			221,057			221,057
Net loss					(434,911)	(434,911)
Ending balance, value at Jun. 30, 2020		$ 20,184	60,076,294	(16,000)	(31,886,862)	28,193,616
Ending balance, shares at Jun. 30, 2020		20,183,939
Issuance of shares		$ 5,600	6,269,464			6,275,064
Issuance of shares, shares		5,600,192
Issuance of common stock in connection with business combination		$ 10,000	12,490,000			12,500,000
Issuance of common stock in connection with business combination, shares		10,000,000
Issuance of warrants for acquisition			1,932,300			1,932,300
Issuance of warrants for services			253,749			253,749
Exercise of options for common stock		$ 54	59,399			59,453
Exercise of options for common stock, shares		54,057
Issuance of common stock for services		$ 50	62,450			62,500
Issuance of common stock for services, shares		50,000
Stock-based compensation expense			802,926			802,926
Net loss					(2,065,043)	(2,065,043)
Ending balance, value at Sep. 30, 2020		$ 35,888	81,946,582	(16,000)	(33,951,905)	48,014,565
Ending balance, shares at Sep. 30, 2020		35,888,188
Beginning balance, value at Dec. 31, 2020		$ 35,928	82,077,334		(36,825,634)	45,287,628
Beginning balance, shares at Dec. 31, 2020		35,928,188
Forgiveness of debt for services
Issuance of shares, shares
Stock-based compensation expense			334,385			334,385
Net loss					(2,211,866)	(2,211,866)
Ending balance, value at Mar. 31, 2021		$ 35,928	82,411,719		(39,037,500)	43,410,147
Ending balance, shares at Mar. 31, 2021		35,928,188
Beginning balance, value at Dec. 31, 2020		$ 35,928	82,077,334		(36,825,634)	45,287,628
Beginning balance, shares at Dec. 31, 2020		35,928,188
Beginning balance, value at Dec. 31, 2020		$ 35,928	82,077,334		(36,825,634)	45,287,628
Net loss						(5,482,793)
Ending balance, value at Sep. 30, 2021		$ 35,928	82,509,957		(42,308,427)	40,237,458
Ending balance, shares at Sep. 30, 2021		35,928,188
Beginning balance, value at Mar. 31, 2021		$ 35,928	82,411,719		(39,037,500)	43,410,147
Beginning balance, shares at Mar. 31, 2021		35,928,188
Stock-based compensation expense			194,657			194,657
Adjustment of warrants value in connection with finalizing the business combination			(732,300)			(732,300)
Net loss					(1,638,928)	(1,638,928)
Ending balance, value at Jun. 30, 2021		$ 35,928	81,874,076		(40,676,428)	41,233,576
Ending balance, shares at Jun. 30, 2021		35,928,188
Stock-based compensation expense			64,074			64,074
Warrants issued in connection with convertible notes			571,807			571,807
Net loss					(1,631,999)	(1,631,999)
Ending balance, value at Sep. 30, 2021		$ 35,928	$ 82,509,957		$ (42,308,427)	$ 40,237,458
Ending balance, shares at Sep. 30, 2021		35,928,188

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss	$ (5,482,793)	$ (2,971,324)	$ (5,845,053)	$ (1,058,039)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization	(76,013)	342,583
Depreciation expense			1,970
Amortization expense			589,489
Stock-based compensation expense	593,116	1,420,451	1,329,643	698,587
Stock-based compensation - restricted common stock	33,333
Interest and accretion	74,410
Issuance of common stock for services			237,500
Debt forgiven and included in operations				30,000
Issuance of warrants for services		253,749	253,749
Change in fair value of contingent liabilities	(472,000)
Change in operating assets and liabilities:
Accounts receivable	(55,706)	(93,010)	(40,585)
Prepaid expense	38,057	(62,487)	307,983	20,000
Inventory	40,950	21,500	127,129
Deposits			(30,000)
Accounts payable and accrued expenses	721,078	140,233	(155,661)	197,438
Due to related parties	272,530
Net cash used in operating activities	(4,313,038)	(948,305)	(3,223,836)	(112,014)
Cash flows used in investing activities:
Purchase of intangible assets		(130,333)	(148,656)	(13,000)
Net cash used in investing activities		(130,333)	(148,656)	(13,000)
Cash flows from financing activities:
Proceeds from promissory notes due to related parties	366,000
Proceeds from convertible notes, net of issuance cost	1,060,949
Issuance of common stock for cash, net of offering costs		6,275,064	6,275,164	125,000
Net cash provided by financing activities	1,426,949	6,275,064	6,275,164	125,000
Net change in cash	(2,886,089)	5,196,426	2,902,672	(14)
Cash at beginning of year	2,902,762	90	90	104
Cash at end of year	16,673	5,196,516	2,902,762	90
Non-cash investing and financing activities:
Derivative liabilities	391,648
Contingent liabilities	9,926,000
Warrants issued in connection with convertible notes	571,807
Issuance of common stock in lieu of payables		261,453
Issuance of common stock in connection with business combination		12,500,000
Issuance of warrants in connection with business combination		$ 1,932,300
Supplemental disclosure of cash flow information:
Cash paid for interest			45,449
Cash paid for taxes
Non-cash investing and financing activities:
Issuance of common stock in lieu of payables			261,453
Issuance of common stock in connection with business combination			12,500,000
Issuance of warrants in connection with business combination			1,932,300
Initial adoption of ROU asset and lease liability			$ 1,317,830

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 - DESCRIPTION OF BUSINESS Maryzime, Inc. (the “Company” or “Marizyme”) is a Nevada corporation originally incorporated on March 20, 2007, under the name SWAV Enterprises, Ltd. On September 6, 2010, the Company name was changed to GBS Enterprises Inc. and from 2010 to September 2018 the Company was in the software products and advisory services business for email and instant messaging applications. The Company divested that business between December 2016 and September 2018 and focused on the acquisition of life science technologies. On March 21, 2018, the Company’s name was changed to Marizyme, Inc., to reflect the new life sciences focus. Marizyme’s common stock is currently quoted on the OTC Markets’ QB tier under the symbol “MRZM”.

GOING CONCERN

GOING CONCERN	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 - GOING CONCERN The Company’s unaudited condensed consolidated financial statements are prepared using principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company does not have an established source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The Company, since its inception, has incurred recurring operating losses and negative cash flows from operations and has an accumulated deficit of $ 42,308,427 at September 30, 2021. Additionally, the Company has negative working capital of $ 2,132,227 16,673 Under the going concern assumption, an entity is ordinarily viewed as continuing its business for the foreseeable future with neither the intention or necessity of liquidation, ceasing trading, or seeking protection from creditors pursuant to the laws and regulations. Accordingly, assets and liabilities are recorded on the basis that the entity will be able to realize its assets and discharge its liabilities in the normal course of business. The ability of the Company to continue as a going concern is dependent upon its ability to continue to successfully develop its intangible assets, receive an approval from the U.S. Federal and Drug Administration (the “FDA”) to extend the selling of the products into the U.S. market which will allow the Company to attain profitable operations. During the next twelve months, the Company’s foreseeable cash requirements will relate to continuous operations of its business, maintaining its good standing and making the required filing with the Securities and Exchange Commission (the “SEC”), and the payment of expenses associated with its product development. The Company may experience a cash shortfall and be required to raise additional capital. Management intends to raise additional funds by way of a private or public offering. While the Company believes in the viability of its strategy to continue to develop and expand its products and generate sufficient revenue and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds by way of a public or private offering. The unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.	NOTE 2 - GOING CONCERN The accompanying consolidated financial statements and the factors within it, have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and the ability of the Company to continue as a going concern for a reasonable period of time. The Company had a net loss of $ 5,845,053 3,223,836 2,384,682 36,825,634

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of the Company and its wholly owned subsidiaries, Somahlution, Inc. (“Somahlution”), Somaceutica, Inc. (“Somaceutica”) and Marizyme Sciences, Inc. (“Marizyme Sciences”). All intercompany transactions have been eliminated on consolidation. The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with generally accepted accounting principles in the U.S. (“U.S. GAAP”). The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on April 15, 2021 (the “2020 Form 10-K”). The balance sheet as of December 31, 2020 was derived from audited consolidated financial statements included in the 2020 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company’s significant accounting policies are described in Note 3 to those consolidated financial statements. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, financial condition, cash flows and stockholders’ equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the allocation of the purchase price in a business combination to the underlying assets and liabilities, recoverability of long-term assets including intangible assets and goodwill, amortization expense, valuation of warrants, stock-based compensation, derivative liabilities, contingent liabilities and deferred tax valuations. Fair Value Measurements The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below: ● Level 1 - Quoted prices for identical assets or liabilities in active markets. ● Level 2 - Quoted prices for identical or similar assets and liabilities in markets that are not active; or other model-derived valuations whose inputs are directly or indirectly observable or whose significant value drivers are observable. ● Level 3 - Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable and for which assumptions are used based on management estimates. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. The carrying amounts of certain cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, and amounts due to related parties approximate fair value due to the short-term nature of these instruments. The contingent liabilities assumed on the acquisition of Somah (Note 4) consist of present values of royalty payments, performance warrants and pediatric voucher warrants, future rare pediatric voucher sales, and liquidation preference. Management measured these contingencies in accordance with Level 3 of the fair value hierarchy. i. The performance warrants and pediatric vouchers warrants liabilities were valued using a Monte Carlo simulation model utilizing the following weighted average assumptions: risk free rate of 1.19 %, expected volatility of 69.62 %, expected dividend of $ 0 , and expected life of 6.21 . For the three and nine months ended September 30, 2021, changes in these assumptions resulted in $ 574,000 1,870,000 decrease in fair value of these liabilities, respectively. At September 30, 2021 the fair market value of performance warrants and pediatric vouchers warrants liabilities was $ 2,899,000 ii. The present value of royalty payments was measured using the scenario-based methodology. In assessing the value attributed to the royalty payments, the estimated future cash flows were discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the revenue from net sales of the product. The cash flows derived from the Company’s fifteen-year strategic plan are based on managements’ expectations of market growth, industry reports and trends, and past performances. These projections are inherently uncertain due to the evolving impact of the COVID-19 pandemic. The discounted cash flow model included projections surrounding revenue, discount rates, and growth rates. The discount rates used to calculate the present value of royalty payments reflect specific risks of the Company and market conditions and the mid-range was estimated at 20.6 %. For the three and nine months ended September 30, 2021, changes in these assumptions resulted in $ 380,000 1,396,000 increase in fair value of these liabilities, respectively. At September 30, 2021 the fair market value of royalty payments was $ 3,582,000 iii. Rare pediatric voucher sales liability was valued based on the scenario-based methodology where the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset - 20.6%. For the three and nine months ended September 30, 2021, changes in these assumptions resulted in $ Nil 2,000 increase in fair value of this liability, respectively. At September 30, 2021 the fair market value of rare pediatric vouchers was $ 1,150,000 iv. The present value of liquidation preference liability, included in the contingent consideration, was determined using the Black-Scholes option pricing method and represents the fair value of the maximum payment amount according to the Agreement. The following assumptions were used in the Black-Scholes option pricing model: risk free rate of 0.21 %, expected volatility of 78.93 %, expected dividend of $ 0 , and expected life of 5 years. No changes to the fair value of liquidation preference liability were recorded in the three and nine months ended September 30, 2021. At September 30, 2021 the fair market value of liquidation preference was $ 1,823,000 The derivative liabilities consisted of optional and automatic conversion features and the share redemption feature attached to the convertible notes, issued pursuant to the Unit Purchase Agreement (Note 9). The Company has no financial assets measured at fair value on a recurring basis. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented. Marizyme measures the following financial instruments at fair value on a recurring basis. As at September 30, 2021, the fair values of these financial instruments were as follows: SCHEDULE OF FAIR VALUES OF FINANCIAL INSTRUMENTS Fair Value Hierarchy September 30, 2021 Level 1 Level 2 Level 3 December 31, 2020 Liabilities Derivative liabilities $ - $ - $ 391,648 $ - Contingent liabilities - - 9,454,000 - Total $ - $ - $ 9,845,648 $ - The following table provides a rollforward of all liabilities measured at fair value using Level 3 significant unobservable inputs: RECONCILIATION OF LIABILITIES AT FAIR VALUE September 30, 2021 Contingent Liabilities Balance at December 31, 2020 - Derivative liabilities $ 391,648 Initial valuation of contingent liabilities in connection with the Somah acquisition 1 9,926,000 Change in fair value of contingent liabilities (472,000 ) Balance at September 30, 2021 $ 9,845,648 1 Measured as at Somah acquisition date of July 31, 2020, see Note 4. Fixed Assets Fixed assets are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method over the assets estimated useful life. Upon the sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in consolidated statements of operations. SCHEDULE OF USEFUL LIFE OF FIXED ASSETS Classification Estimated Useful Lives Equipment 5 to 7 years Furniture and fixtures 4 to 7 years Intangible Assets and Goodwill Intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. Intangible assets acquired as a result of an acquisition or in a business combination are measured at fair value at the acquisition date. The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized over the estimated useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimates being accounted for on a prospective basis. Goodwill represents the excess of the purchase price paid for the acquisition of subsidiaries over the fair value of the net assets acquired. Following the initial recognition, goodwill is measured at cost less any accumulated impairment losses. In-Process Research and Development The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. Impairment of Long-Lived Assets The Company reviews long-lived assets, including property, plant and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. No Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested common stock, options and warrants. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities (warrants, stock options, and common shares subject to repurchase) would be antidilutive. The following is a reconciliation of basic and diluted earnings (loss) per common share for the years ended December 31, 2020 and 2019: SCHEDULE OF RECONCILIATION OF BASIC AND DILUTED EARNINGS (LOSS) For the Years Ended December 31, 2020 2019 Basic and diluted earnings per common share Numerator: Net loss available to common shareholders $ (5,845,053 ) $ (1,058,039 ) Denominator: Weighted average common shares outstanding 26,373,982 19,805,959 Basic and diluted loss per common share $ (0.22 ) $ (0.05 ) Recently Adopted Accounting Standards There are no recently adopted accounting standards and recent accounting standards not yet adopted that the Company believes will have a material impact on the Company’s unaudited condensed consolidated financial statements. Recently Issued Accounting Pronouncements The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board or other standard setting bodies on the Company’s financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. There were no new material accounting standards issued in the nine months ended September 30, 2021, that impacted the Company. COVID-19 Since December 31, 2019, the outbreak of the novel strain of coronavirus, specifically identified as “COVID-19”, has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures, which include the implementation of travel bans, self-imposed quarantine periods and physical distancing, have caused material disruptions to businesses globally resulting in an economic slowdown. Global equity markets have experienced significant volatility and weakness. The duration and impact of the COVID-19 outbreak is unknown at this time, as is the efficacy of the government and central bank interventions. It is not possible to reliably estimate the length and severity of these developments and the impact on the financial results and condition of the Company in future periods. Marizyme continues to maintain business continuity during the COVID-19 pandemic and takes its cues from the U.S. government and public health officials to keep employees and business partners safe and healthy. Although the financial results for three and nine months ended September 30, 2021 were not significantly impacted by COVID-19, Marizyme experienced decrease in sales due to a slow-down in the product manufacturing. During 2021, Marizyme’s business partners were focused on addressing specific manufacturing needs of the U.S. government in battling COVID-19 pandemic. Additionally, during 2021, demand for elective surgeries have decreased due to overloaded medical systems and potential risks related to patients’ recovery during the pandemic. The Company cannot predict the impact of the progression of COVID-19 on future results or the Company’s ability to raise capital due to a variety of factors, including but not limited to the continued good health of Company employees, the ability of suppliers to continue to operate and deliver, the ability of the Company to maintain operations, any further government and/or public actions taken in response to the pandemic and ultimately the length of the pandemic.	NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The Company follows the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP). Principles of Consolidation The accompanying consolidated financial statements include all of the accounts of the Company and its wholly owned subsidiaries, Somahlution, Inc. (“Somahlution”), Somaceutica, Inc. (“Somaceutica”) and Marizyme Sciences, Inc. (“Marizyme Sciences”). All significant intercompany balances and transactions have been eliminated. Use of Estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the allocation of the purchase price in a business combination to the underlying assets and liabilities, allowance for doubtful accounts, recoverability of long-term assets including intangible assets and goodwill, amortization expense, inventory valuation, valuation of warrants, stock-based compensation, and deferred tax valuations. Business Combinations The Company accounts for business acquisitions using the acquisition method of accounting based on Accounting Standards Codification (“ASC”) 805 — Business Combinations, which requires recognition and measurement of all identifiable assets acquired and liabilities assumed at their fair value as of the date control is obtained. The Company determines the fair value of assets acquired and liabilities assumed based upon its best estimates of the acquisition-date fair value of assets acquired and liabilities assumed in the acquisition. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Subsequent adjustments to fair value of any contingent consideration are recorded to the Company’s consolidated statements of operations. Stock-Based Compensation Stock-based compensation expense is recorded in accordance with FASB ASC Topic 718, Compensation – Stock Compensation, for stock and stock options awarded in return for services rendered. The expense is measured at the grant-date fair value of the award and recognized as compensation expense on a straight-line basis over the service period, which is the vesting period. The Company estimates forfeitures that it expects will occur and records expense based upon the number of awards expected to vest. The fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model. Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. At December 31, 2020 and 2019, the Company had no Reclassifications Certain amounts in the prior year’s consolidated financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported. The reclassifications were for the Statement of Operation which combined its expenses into two categories whereas, for comparison purposes for the years ended December 31, 2020 to December 31, 2019, professional fees and stock-based compensation was segregated. Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure trade and notes receivable are not overstated due to non-collectability. The Company’s allowance is based on a variety of factors, including age of the receivable, significant one-time events, historical experience, and other risk considerations. The Company did no no Inventory Inventory consisted of primarily finished goods and is valued at the lower of cost or net realizable value. Inventory is held in a third-party warehouse in foreign countries. Cost is determined using the FIFO method. The Company decreases the value of inventory for estimated obsolescence equal to the difference between the cost of inventory and the estimated market value, based upon an aging analysis of the inventory on hand, specifically known inventory-related risks, and assumptions about future demand and market conditions. The Company has determined that no Fair Value of Financial Instruments Fair Value Measurements The Company measures its financial assets and liabilities in accordance with FASB ASC 820 (the “Fair Value Topic”). For certain of our financial instruments, including cash, accounts payable, accrued expenses, and short-term loans the carrying amounts approximate fair value due to their short maturities. We follow accounting guidance for financial and non-financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. The Company had no Fixed Assets Fixed assets are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method over the assets estimated useful life. Upon the sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in consolidated statements of operations. SCHEDULE OF USEFUL LIFE OF FIXED ASSETS Classification Estimated Useful Lives Equipment 5 7 Furniture and fixtures 4 7 Intangible Assets Intangible Assets and Goodwill Costs incurred to file patent applications and acquired intangibles are capitalized when the Company believes that there is a high likelihood that the patent will be issued and there will be future economic benefit associated with the patent. These costs will be amortized on a straight-line basis over a 20 Impairment of Long-lived Assets The Company follows ASC 360 for its long-lived assets. The Company’s long-lived assets, such as intellectual property, are required to be reviewed for impairment annually, or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The Company assesses the recoverability of its long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives. The Company determined that there were no Revenue Recognition We recognize revenue under Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, (“ASC 606”). The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. We only apply the five-step model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the goods and services transferred to the customer. The following five steps are applied to achieve that core principle: Step 1: Identify the contract with the customer Step 2: Identify the performance obligations in the contract Step 3: Determine the transaction price Step 4: Allocate the transaction price to the performance obligations in the contract Step 5: Recognize revenue when the company satisfies a performance obligation We have identified one performance obligation which is related to our DuraGraft product sales. For our Distribution Partner channel, we recognize revenue for product sales at the time of delivery of the product to our Distribution Partner (customer). The customer is invoiced, and Payment Terms are Net 30. As our products have an expiration date, if a product expires, we will replace the product at no charge. Revenue disaggregation for year ended December 31, 2020 amount to $ 71,610 23,080 63,110 39,336 In the transaction that acquired the assets of Somahlution, LLC, the Company determined that the CE mark for Europe must be in Marizyme, Inc. in order for Somahlution, Inc. to bill revenue and receive the payments accordingly. The Company has filed in Europe for the CE mark to be in Marizyme, Inc. but, until the time it is approved by the Notified Body, BSI (British Standards Institution), which is projected for May 2021, Somahlution, LLC provides the billing and receiver of funds. On a periodical basis, the cash received is transferred to Somahlution, Inc. Direct Cost of Revenue Cost of sales includes the actual cost of merchandise sold; the cost of transportation of merchandise from our third-party vendor to our distributer. Net Income (Loss) per Share The Company computes basic and diluted income (loss) per share amounts pursuant to ASC 260 of the FASB Accounting Standards Codification. Basic loss per share is computed by dividing net loss available to common stockholders, by the weighted average number of shares of common stock outstanding during the period, excluding the effects of any potentially dilutive securities. Diluted loss per share is computed by dividing net loss available to common stockholders by the diluted weighted average number of shares of common stock during the period. The diluted weighted average number of common shares outstanding is the basic weighted number of shares adjusted as of the first day of the year for any potentially diluted debt or equity. The following is a reconciliation of basic and diluted earnings (loss) per common share for the years ended December 31, 2020 and 2019: SCHEDULE OF RECONCILIATION OF BASIC AND DILUTED EARNINGS (LOSS) For the Years Ended December 31, 2020 2019 Basic and diluted earnings per common share Numerator: Net loss available to common shareholders $ (5,845,053 ) $ (1,058,039 ) Denominator: Weighted average common shares outstanding 26,373,982 19,805,959 Basic and diluted loss per common share $ (0.22 ) $ (0.05 ) Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and loss carryforwards and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rules on deferred tax assets and liabilities is recognized in operations in the year of change. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of December 31, 2020 and 2019. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as interest expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the years ended December 31, 2020 and 2019. Segment Information Segment Reporting In accordance with the provisions of ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information,” the Company is required to report financial and descriptive information about its reportable operating segments. The Company has one Effect of Recent Accounting Pronouncements Accounting Standards Adopted During the Year Ended December 31, 2020 The Company adopted Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), as of January 1, 2020, using the modified retrospective approach. The modified retrospective approach provides a method for recording existing leases at the application date. In addition, the Company elected the available practical expedients permitted under the transaction guidance within the new standard. The most significant impact from the adoption of the new standard was the recognition of operating lease right-of-use assets and operating lease liabilities. The Company entered into a new lease in December 2020 which resulted in the recording of additional lease assets and liabilities with a balance of $ 1,317,830 Recently Issued Accounting Standards Not Yet Adopted The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its consolidated financial statements. Concentration of Credit Risk The Company places its temporary cash investments with financial institutions insured by the FDIC. The Company has amounts over insured limits. Amounts on deposit may at times exceed the FDIC insurance limit. The Company has not experienced any losses in such accounts. Customer Concentrations For the year ended December 31, 2020, four customers made up 100 100 no Research and Development In-Process Research and Development All research and development costs, payments to laboratories and research consultants are expensed when incurred.

ACQUISITIONS

ACQUISITIONS	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Business Combination and Asset Acquisition [Abstract]
ACQUISITIONS	NOTE 4 - ACQUISITIONS DuraGraft® On December 15, 2019, the Company entered into a contingent asset purchase agreement (the “Agreement”), as amended on March 31, 2020 and May 29, 2020, with Somahlution, LLC, Somahlution, Inc., and Somaceutica, LLC, companies duly organized under the laws of Delaware (collectively, “Somah” or “Seller”) to acquire all of the assets and none of the liabilities of Somah (the “Acquisition”), including DuraGraft®, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. On July 31, 2020, the Company and Somah entered into Amendment No. 3 to the Agreement and the Agreement was finalized. Pursuant to the terms of this amendment, it was agreed that, as part of the Acquisition, the Company would acquire the outstanding capital stock of Somahlution, Inc., held by Somahlution, LLC, rather than the assets of Somahlution, Inc. This change to the Agreement was made to accommodate the European Union (“EU”) requirements with respect to the future manufacturing under Somahlution, Inc. of CE marked products for sale in the EU. In Amendment No. 3, the Company agreed to assume certain payables of Somah related to clinical and medical expenses. It was agreed that the payments on the assumed debts would be recorded as a prepaid royalty against future royalties. As of September 30, 2021 and December 31, 2020, prepaid royalties were $ 340,969 344,321 Pursuant to the Agreement and in consideration of the outstanding capital stock of Somahlution, Inc., the Company agreed to issue to Somah: ● 10,000,000 ● Warrants to purchase 3,000,000 5.00 five years ● The Company, on a pro rata basis, shall grant the Seller the following contingent consideration upon receiving the FDA final approval and insurance reimbursement approval on the product: ○ Grant of performance warrants for 4,000,000 ○ Royalties to be paid on all net sales of the product acquired from Somah of 6 50 5 50 4 50 200 2 200 ○ Payment of 10% of cash value of the rare pediatric voucher sales following the FDA approval and subsequent sale to an unaffiliated third party of a rare pediatric voucher based on Somah’s DuraGraft product; ○ Grant of rare pediatric voucher warrants to purchase an aggregate of 250,000 ○ Liquidation preference, up to a maximum of $ 20 On July 30, 2020, the Company completed the acquisition of Somah (the “Somah Transaction”). The acquisition of Somah provides the Company with access to DuraGraft and other related intangible assets, which upon approval by FDA, will further the Company’s continued growth and international-wide product rollout. In accordance with ASC 805-10 the substance of a transaction constitutes a business combination as the business of Somah meets the definition of a business under the standard. Accordingly, the transaction was accounted for in accordance with the acquisition method of accounting, and the assets acquired, and the liabilities assumed have been recorded at their respective estimated fair values as of the acquisition date. The purchase price is based on management’s estimate of fair value of the common shares and warrants issued as well as contingent consideration and liquidation preference given up. The final allocation of the purchase price consideration to the assets acquired and liabilities assumed has been completed and finalized. Details of the carrying amount and the fair value of identifiable assets and liabilities acquired and purchase consideration paid are as follows: SCHEDULE OF PRELIMINARY ALLOCATION OF CONSIDERATION Consideration Common shares $ 12,500,000 Warrants 1,200,000 Contingent consideration 1 9,926,000 Total consideration $ 23,626,000 Fair value of identifiable assets acquired, and liabilities assumed Net working capital $ 30,908 Property, plant, and equipment 9,092 Receivables - Inventory - Intangible assets 18,170,000 Goodwill 5,416,000 Total identifiable assets $ 23,626,000 1 Contingent consideration, for the purposes of the final allocation of the purchase price consideration, was measured as at the date of Somah acquisition - July 31, 2020. During the nine months ended September 30, 2021, the fair market value of the contingent liabilities, measured in accordance with Level 3 of the fair value hierarchy, has decreased by $ 472,000 The intangible assets acquired include: ● DuraGraft patent, with estimated remaining economic life of 13 ● “Distribution relationships” intangible asset related to DuraGraft products, with estimated remaining economic life of 10 ● In-process research and development intangible asset - “Cyto Protectant Life Sciences” with indefinite economic life. Goodwill is attributed to the workforce and profitability of the acquired business and is not deductible for tax purposes. A residual method methodology was used to estimate the fair market value goodwill. A pre-tax discount rate based on weighted average cost of capital of 33.8 Pro-forma revenue, net income, and earnings per share are not presented for this acquisition as they are not material.	NOTE 5 – ACQUISITIONS Krillase On September 12, 2018, the Company consummated an asset acquisition with ACB Holding AB, Reg. No. 559119-5762, a Swedish corporation to acquire all right, title and interest in their Krillase technology in exchange for 16.98 28,600,000 During 2020, the Company incurred legal and filing fees of $ 17,801 DuraGraft® On December 15, 2019, the Company entered into a contingent asset purchase agreement (the “Agreement”), as amended on March 31, 2020 and May 29, 2020, with Somahlution, LLC, Somahlution, Inc., and Somaceutica, LLC, companies duly organized under the laws of Delaware (collectively, “Somah”) to acquire all of the assets and none of the liabilities of Somah (the “Acquisition”), including DuraGraft®, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. On July 31, 2020, the Company and Somah entered into Amendment No. 3 to the Agreement and the Agreement was finalized. Pursuant to the terms of this amendment, it was agreed that, as part of the Acquisition, the Company would acquire the outstanding capital stock of Somahlution, Inc., held by Somahlution, LLC, rather than the assets of Somahlution, Inc. This change to the Agreement was made to accommodate the European Union (“EU”) requirements with respect to the future manufacturing under Somahlution, Inc. of CE marked products for sale in the EU. In Amendment No. 2, the Company agreed to assume certain payables of Somah related to clinical and medical expenses. These assumed payables were $ 344,321 344,321 The Company compensated the Somah stockholders as follows: (1) 10,000,000 1.25 4,610,064 1.25 7,000,240 5,600,272 1.25 3,000,000 5.00 five years 6 50 4 50 200 2 200 The Company is in the process of determining the fair value of the royalty component of the total consideration as well as the identifiable intangible assets acquired in business combination. The Company is using a third-party valuation firm and at this time we are unable to estimate the contingent consideration related to the future royalty payment stream amount accurately. As such, the following table represents the preliminary consideration in connection with the transaction excluding the fair value of the royalty payment stream: SCHEDULE OF PRELIMINARY ALLOCATION OF CONSIDERATION Consideration given: Common stock shares given $ 12,500,000 Warrants given 1,932,300 Total consideration given $ 14,432,300 Fair value of identifiable assets acquired, and liabilities assumed: Receivables $ 45,845 Inventory 229,635 Fixed assets 9,092 Intangible assets 14,147,728 Total identifiable net assets $ 14,432,300 The Company anticipates a significant fair value to be assigned to identifiable intangible assets such as in process research and development and patents. Included in the preliminary allocation to the fair value of assets acquired and liabilities assumed is an 100 589,489 Dr. Vithal D. Dhaduk, a co-founder of Somahlution, LLC (“Dhaduk”), is the subject of a complaint filed in the United States District Court, Middle District of Pennsylvania, Civil Action No. 3:17 cv 02243 in December 2017 by Mukeshkkumar B. Patel (“Patel”), a former business partner of Dhaduk, which complaint makes claims of breach of contract, promissory estoppel and unjust enrichment regarding a Memorandum of Understanding, dated July 16, 2015, between Patel and Dhaduk (“MOU”). The MOU provided that Dhaduk would pay Patel $ 9.45

LEASES

LEASES	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Leases
LEASES	NOTE 5 – LEASES On December 11, 2020, the Company entered into a 5.5 10,817 2.5 12,000 4.67 The assets and liabilities from the lease were recognized at the lease commencement date based on the present value of remaining lease payments over the lease term using the discount rate of 3.95 The total rent expense for the three months ended September 30, 2021 and 2020 was $ 77,357 Nil 168,769 Nil The following table summarizes supplemental balance sheet information related to the operating lease as of September 30, 2021 and December 31, 2020. SCHEDULE OF RIGHT-OF-USE ASSET AND RELATED LEASE LIABILITY September 30, 2021 December 31, 2020 Right-of-use asset $ 1,163,159 $ 1,317,830 Operating lease liabilities, current $ 260,106 $ 243,292 Operating lease liabilities, non-current 941,732 1,074,538 Total operating lease liabilities $ 1,201,838 $ 1,317,830 As at September 30, 2021, the maturities of the lease liabilities for the periods ended December 31 were as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES 2021 $ 52,249 2022 277,142 2023 277,142 2024 277,142 2025 277,142 2025 Thereafter 130,950 Total lease payments 1,291,767 Total lease payments 1,291,767 Less: present value discount (89,929 ) Total $ 1,201,838	NOTE 4 – LEASE LEASES Effective January 1, 2020, the Company adopted the provision of Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842). The provisions of this ASU require the Company to record a right-of-use asset and related lease liability related to their leases. The Company leases its administrative office and laboratories under an operating lease agreement. The Company entered into an agreement in December 2020 for approximately 8,500 square feet which is for a five-and-one-half year period. 10,817 12,000 2.5 second year Right-Of-Use Asset and Lease Liability: The Company’s consolidated balance sheets reflect the value of the right-of-use asset and related lease liability. This value was calculated based on the present value of the remaining base rent lease payments. The discount rate used was 3.95 SCHEDULE OF RIGHT-OF-USE ASSET AND RELATED LEASE LIABILITY December 31, 2020 2019 Right-of-use asset $ 1,317,830 $ - Total lease liability $ 1,317,830 $ - Less: Current portion 243,292 - Lease liability, net of current portion $ 1,074,538 $ - The maturities of the lease liabilities are as follows as of December 31, 2020: SCHEDULE OF MATURITIES OF LEASE LIABILITIES 2021 $ 208,997 2022 277,142 2023 277,142 2024 277,142 2025 277,142 Thereafter 130,950 Total lease payments 1,470,148 Less: Present value discount (152,318 ) Total $ 1,317,830 For the year ended December 31, 2020, operating cash flows paid in connection with operating leases amounted to $ 21,633

PROPERTY, PLANT AND EQUIPMENT,

PROPERTY, PLANT AND EQUIPMENT, NET	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	NOTE 6 - PROPERTY, PLANT AND EQUIPMENT, NET Property, plant and equipment, summarized by major category, stated at cost, less accumulated depreciation at September 30, 2021 and December 31, 2020 consisted of the following: SCHEDULE OF PROPERTY PLANT & EQUIPMENT September 30, 2021 December 31, 2020 Furniture and equipment $ 701 $ 701 Computer related 7,220 7,220 Machinery and equipment 1,171 1,171 Total $ 9,092 $ 9,092 Less: accumulated amortization (7,819 ) (1,970 ) Property, plant and equipment, net $ 1,273 $ 7,122 Depreciation expense for the three months ended September 30, 2021 and 2020 was $ 1,425 1,313 5,849 1,313	NOTE 7 – FIXED ASSETS PROPERTY, PLANT AND EQUIPMENT, NET Fixed assets, stated at cost, less accumulated depreciation at December 31, 2020 and 2019 consisted of the following: SCHEDULE OF PROPERTY PLANT & EQUIPMENT 2020 2019 December 31, 2020 2019 Furniture and equipment $ 701 $ - Computer related 7,220 - Machinery and equipment 1,171 - Total 9,092 - Less: accumulation depreciation (1,970 ) - Property and equipment, net $ 7,122 $ - Depreciation expense for the years ended December 31, 2020 and 2019 was $ 1,970 0

INTANGIBLE ASSETS

INTANGIBLE ASSETS	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 7 - INTANGIBLE ASSETS Krillase As part of the asset acquisition of ACB Holding AB, Reg. No. 559119-5762, completed on September 12, 2018, Marizyme acquired all rights, titles, and interest in the Krillase technology, a group of intangible assets worth $ 28,600,000 The Company anticipates Krillase being placed into service in 2023. The Company has evaluated this asset for impairment and has determined that due to COVID-19 delaying the next steps for roll out of this technology, along with the associated value of the research and development, the status of the clinical trials, and other pertinent proprietary technology, there is no impairment required. DuraGraft As part of Somah acquisition (Note 4), Marizyme purchased $ 18,170,000 of intangible assets related to the DuraGraft® technology. SUMMARY OF INTANGIBLE ASSETS AMORTIZATION EXPENSE September 30, 2021 December 31, 2020 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Krillase intangible assets $ 28,600,000 $ - $ 28,600,000 $ 28,600,000 $ - $ 28,600,000 DuraGraft patent 5,256,000 (471,691 ) 4,784,309 14,147,729 (589,489 ) 13,558,240 Distributor relationship 308,000 (35,933 ) 272,067 - - - IPR&D - Cyto Protectant Life Sciences 12,606,000 - 12,606,000 - - - Patents in process 122,745 - 122,745 119,971 - 119,971 Total intangibles $ 46,892,745 $ (507,624 ) $ 46,385,121 $ 42,867,700 $ (589,489 ) $ 42,278,211 The following changes to the Company’s intangible assets had taken place in the periods indicated: SCHEDULE OF INTANGIBLE ASSETS Balance, December 31, 2019 $ 28,613,000 Acquired in asset purchase agreement 14,147,729 Additions 106,971 Amortization expense (589,489 ) Accumulated amortization (589,489) Balance, December 31, 2020 42,278,211 Acquired in Somah Transaction 1 4,022,271 Additions 2,775 Amortization expense 1 81,864 Balance, September 30, 2021 $ 46,385,121 1 To account for Somah Transaction measurement period adjustments, the Company restated the Quarterly Report on Form 10-Q for the three and six month ended June 30, 2021, originally filed on August 23, 2021. As a result of the restatement, the value of DuraGraft intangibles purchased with the Somah Transaction increased by $ 4,022,271 898,026 The Company has recorded amortization expense of $ 108,777 326,331 341,270 Future amortizations for DuraGraft related intangible assets for the next five years will be $ 435,108 for each year from 2021 through 2026 and $ 2,880,836 for 2027 and thereafter. Amortization related to in process research and development will be determined upon the Company achieving commercialization.	NOTE 8 – INTANGIBLE ASSETS On September 12, 2018, the Company consummated an asset acquisition with ACB Holding AB, Reg. No. 559119-5762, a Swedish corporation to acquire all right, title and interest in their Krillase technology in exchange for 16.98 During 2020, the Company incurred legal and filing fees of $ 17,801 On July 31, 2020, the Company executed an agreement with Somah (see Note 4) for the DuraGraft® technology in exchange for 10,000,000 3,000,000 SUMMARY OF INTANGIBLE ASSETS AMORTIZATION EXPENSE December 31, 2020 December 31, 2019 Gross Net Gross Net Carrying Accumulated Carrying Carrying Accumulated Carrying Amount Amortization Amount Amount Amortization Amount Krillase - Patents, Patent Applications, Research and Development, Clinical Trials, Developed Technology $ 28,600,000 $ - $ 28,600,000 $ 28,600,000 $ - $ 28,600,000 DuraGraft - Patents, Patent Applications, Research and Development, Clinical Trials, Developed Technology 14,147,729 (589,489 ) 13,558,240 - - - Patents in process 119,971 - 119,971 13,000 13,000 Total Intangibles $ 42,867,700 $ (589,489 ) $ 42,278,211 $ 28,613,000 $ - $ 28,613,000 For the year ended December 31, 2020, changes to intangible assets were as follows: SCHEDULE OF INTANGIBLE ASSETS Balance, December 31, 2019 $ 28,613,000 Acquired in asset purchase agreement 14,147,729 Additions 106,971 Accumulated amortization (589,489 ) Balance, December 31, 2020 $ 42,278,211 The Company has recorded amortization expense of $ 589,489 The useful lives of the intangible assets are based on the life of the patent and related technology. The patents and related technology for Krillase are not currently being amortized as they have not yet been put into operations. Future amortizations for DuraGraft related intangible assets for the next five years will be $ 1,414,773 825,284

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 8 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses, summarized by major category, as of September 30, 2021 and December 31, 2020 consists of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES September 30, 2021 December 31, 2020 Trade accounts payable $ 1,117,517 $ 325,830 Accrued expenses 180,846 21,555 Accrued compensation expenses 98,582 130,718 Total accounts payable and accrued expenses $ 1,396,945 $ 478,103

CONVERTIBLE PROMISSORY NOTES AN

CONVERTIBLE PROMISSORY NOTES AND WARRANTS	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
CONVERTIBLE PROMISSORY NOTES AND WARRANTS	NOTE 9 - CONVERTIBLE PROMISSORY NOTES AND WARRANTS On May 27, 2021, the Company entered into a Unit Purchase Agreement (“Unit Purchase Agreement”) to sell up to 4,000,000 2.50 Each Unit is comprised of (i) a convertible promissory note (the “Convertible Note”) convertible into common stock of the Company at a price per share of $2.50, (ii) a warrant to purchase one share of common stock of the Company (the ‘Class A Warrant’); and (iii) a second warrant to purchase common stock of the Company (the “Class B Warrant”). In May 2021, the Company issued and sold 29,978 2.50 74,945 74,945 29,978 29,978 6,745 In July 2021, the Company issued and sold 440,000 1,100,000 1,100,000 440,000 440,000 99,000 On September 29, 2021, the Company, with the consent of all Unit holders, amended the May 2021 Unit Agreements. By rescinding their investment, the Unit holders agreed to amend the Unit Purchase Agreement resulted in the following changes to the offering: (i) Decreased the offering price under the Unit Purchase Agreement from $ 2.50 2.25 (ii) Decreased the conversion price from $ 2.50 2.25 (iii) Cancelled all Class A Warrants and Class B Warrants and replaced them with Class C Warrants. The Company determined that the modifications of Unit Purchase Agreement were not significant enough to be considered substantial, therefore the values of original instruments issued were not adjusted. As a result of this modification, the total of 469,978 522,198 The Company determined that the optional and automatic conversion feature and the share redemption feature attached to the convertible notes meet the definition of derivative liabilities and that the detachable warrants issued do not meet the definition of a liability and therefore will be accounted for as an equity instrument. The initial $ 571,807 fair value of the warrants and $ 391,648 fair value of derivative liabilities issued have been recorded as debt discount and are being amortized to interest and accretion expense using the effective interest method over the term of the Convertible Notes. SCHEDULE OF CONVERTIBLE NOTES September 30, 2021 December 31, 2020 Convertible notes issued $ 1,174,945 $ Issuance costs (105,745 ) - Debt discount (964,153 ) - Debt accretion 74,410 - Convertible notes, net of debt discount $ 179,457 $ - During the three and nine months ended September 30, 2021, the Company recognized interest and accretion expense of $ 70,221 and $ 74,410 , respectively (September 30, 2020 - $ Nil and $ Nil ) in the condensed consolidated statements of operations. Convertible Notes Terms The Convertible Notes mature in 24 months from the initial closing date and accrue 10 The Convertible Notes principal and accrued interest can be converted at any time at the option of the holder at a conversion price of $2.25 per share (before the modification - $2.50 per share) 10,000,000 75 2.25 Warrants Terms Class A ● Exercise price is the lower of (i) $ 3.13 75 2.50 ● Exercisable for a period of 5 ● Warrant Coverage: 100 Class B ● Exercise price is $ 5.00 ● Exercisable for a period of 5 ● Warrant Coverage: 100 Class C ● Exercise price is the lower of (i) $ 2.25 75 2.25 ● Exercisable for a period of 5 ● Warrant Coverage: 200

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 10 - STOCKHOLDERS’ EQUITY a) Preferred stock The Company is authorized to issue a total number of 25,000,000 0.001 no b) Common stock The Company is authorized to issue a total number of 75,000,000 0.001 As of September 30, 2021 and December 31, 2020, there were 35,928,188 c) Options On January 13, 2021, the Board of Directors approved the Marizyme’s 2021 Stock Incentive Plan (“SIP”). The SIP incorporates stock options issued prior to January 13, 2021. The SIP authorized 5,300,000 1,527,183 During the nine months ended September 30, 2021, the company granted 732,500 1,340,000 SCHEDULE OF SHARE BASED STOCK OPTION VALUATION ASSUMPTIONS 2021 2020 Risk-free interest rate 0.69 % 0.93 % Volatility 232.69 % 241.88 % Exercise price $ 1.25 $ 1.37 Dividend yield 0 % 0 % Forfeiture rate 0 % 0 % Expected life (years) 3 10 The Company recognizes forfeitures as they occur. The summary of option activity for the nine months ended September 30, 2021 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY Number of Weighted Weighted Total Intrinsic Outstanding at December 31, 2019 2,715,000 $ 1.50 9.48 $ N/A 1 Granted 1,340,000 1.25 Exercised (254,057 ) 1.02 Outstanding at December 31, 2020 3,800,943 $ 1.36 8.82 $ 123,600 Granted 732,500 1.25 Forfeited (760,626 ) 1.25 Outstanding at September 30, 2021 3,772,817 $ 1.37 8.13 $ 97,850 Exercisable at September 30, 2021 3,074,476 $ 1.39 3.77 $ 97,850 1 SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE Number of Number of Remaining Exercise Options Options Life in Intrinsic Price Outstanding Exercisable Term Years Value $ 1.01 515,000 515,000 10 7.93 8.03 $ 123,600 $ 1.25 890,000 14,167 10 9.81 9.92 - $ 1.37 200,000 30,000 10 9.63 - $ 1.50 2,195,943 2,195,943 10 8.53 - 3,800,943 2,755,110 $ 123,600 d) Warrants The warrant activity for the periods presented is as follows: SCHEDULE OF OPTIONS OUTSTANDING AND ISSUED Number Weighted Average December 30, 2019 113,637 $ 3.00 Issued on Somah acquisition (Note 4) 3,000,000 5.00 Issued 280,014 1.38 December 30, 2020 3,393,651 $ 2.13 Issued 1,044,396 2.25 September 30, 2021 4,438,047 $ 2.16 During the three and nine months ended September 30, 2021, the Company issued the following: On May 27, 2021, pursuant to the Unit Purchase Agreement (Note 9) the Company issued Class A Warrants for the purchase of 29,978 29,978 3.13 five years 5.00 five years In July 2021 pursuant to the May Unit Purchase Agreement the Company issued Class A Warrants for 440,000 440,000 On September 29, 2021, pursuant to the modification to the Unit Purchase Agreement as described in Note 9, all Class A and Class B warrants were replaced with an aggregate of 1,044,396 pro-rata Class C warrants. The warrants have a strike price of 2.25 per share and a term of five years . The detachable warrants issued were accounted for as an equity instrument and were ascribed the fair market value of $571,807 using the residual fair value allocation method. During the year end December 31, 2020, the Company issued the following: On July 31, 2020, the Company completed the Somah Acquisition (Note 4) whereas 10,000,000 3,000,000 5.00 five years 0.40 1,200,000 On September 25, 2020, the Company issued two warrants for services. The warrants were to purchase for 168,008 112,006 1.375 five years 0.9062 152,249 101,500 253,749 e) Stock-based compensation During the three and nine month ended September 30, 2021, the Company recorded $ 64,074 and $ 593,116 , respectively, in non-cash share-based compensation (September 30, 2020 - $ 1,107,085 and $ 1,674,200 respectively). Additionally, the Company recognized $ 33,333 of stock-based compensation on restricted common stock in the nine months ended September 30, 2021. As of September 30, 2021, the Company had $ 652,932 2.44	NOTE 10 – STOCKHOLDERS’ EQUITY Preferred stock Our Articles of Incorporation authorize the issuance of 25,000,000 0.001 As of December 31, 2020, and 2019, there were no Common stock Our Articles of Incorporation authorize the issuance of 75,000,000 0.001 As of December 31, 2020, there were 35,928,188 19,858,939 The following transactions in the Company’s common stock were completed in the year ended December 31, 2020: On January 9, 2020, the Company issued 125,000 126,250 On April 6, 2020, the Company issued 160,000 160,000 161,600 On April 6, 2020, the Company issued 5,000 5,050 On April 6, 2020, the Company issued 15,000 15,150 On June 8, 2020, the Company issued 20,000 20,200 On July 28, 2020, the Company issued 64,057 59,453 On July 28, 2020, the Company issued 20,000 25,000 On July 31, 2020, the Company completed the Soma Acquisition (see Note 3) whereas 10,000,000 3,000,000 12,500,000 1,932,300 On August 3, 2020, the Company completed an initial closing of a private placement (the “Private Placement”) with certain accredited investors (the “Investors”) pursuant to which the Company sold and issued to the Investors an aggregate of 4,609,984 1.25 In consideration for services rendered as the placement agent in the Private Placement, on August 2, 2020, the Company paid Univest Securities LLC cash commissions totaling $ 460,999 57,625 31,250 229,499 1.375 100 On September 1, 2020, the Company issued 40,000 one On September 25, 2020, the Company closed on the second tranche of funding in the gross amount of $ 1,237,760 990,208 1,116,566 On October 1, 2020, the Company entered into a consulting agreement which had various compensation requirements, including the issuance of 20,000 shares of common stock (valued at $ 1.25 36,364 1.375 The following transactions in the Company’s capital stock were completed in the year ended December 31, 2019: On June 12, 2019, the Company issued 90,910 1.10 100,000 27,727 0.9016 25,000 3.00 Options The summary of option activity for the years ended December 31, 2020 and 2019 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY Weighted Weighted Average Average Total Number of Exercise Contractual Intrinsic Options Price Life Value Outstanding at December 31, 2018 265,000 $ 1.50 Granted 2,450,000 $ 1.01 Exercised - $ - Forfeited - $ - Outstanding at December 31, 2019 2,715,000 $ 1.50 Granted 1,340,000 $ 1.25 Exercised (254,057 ) $ 1.02 Forfeited - $ - Outstanding at December 31, 2020 3,800,943 $ 1.36 8.82 $ 123,600 Exercisable at December 31, 2020 2,755,110 $ 1.40 The fair value of each stock option was estimated using the Black Scholes pricing model which takes into account as of the grant date the exercise price (ranging from $ 1.01 1.37 10 179.31 304.44 0 .93 The following stock options were granted during the past year: On January 9, 2020, the Company issued 250,000 1.01 10 25,000 222,385 1.01 On August 18, 2020, the Company issued 200,000 1.37 10 eighteen months 66,024 1.25 175,000 On October 22, 2020, the Company issued 50,000 three 1.25 10 2,604 1.2453 59,671 On October 22, 2020, the Company issued 120,000 three 1.25 10 6,250 On March 5, 2021, the Company accelerated the vesting to 50% as of this date and the remaining 50% as of October 22, 2021 (see Note 12 1.2453 143,210 On October 30, 2020, the Company issued 125,000 three 1.25 10 6,510 1.2454 149,189 On November 1, 2020, Dr. Neil J. Campbell executed an employment agreement and was named as chief executive officer, president and director. He received 500,000 three years 1.25 10 26,042 1.2454 596,754 On November 9, 2020, the Company issued 15,000 three years 1.25 10 868 1.2445. 17,806 On December 1, 2020, the Company issued 40,000 three years 1.25 10 2,083 1.2462 47,771 On December 2, 2020, the Company issued 40,000 three years 1.25 10 1,330 1.2461. 47,767 The weighted average grant date fair value of options granted during 2020 was $ 1.25 As of December 31, 2020, the total unamortized stock-based compensation expense amounted to $ 1,237,167 As of December 31, 2020, the number of options outstanding and exercisable are as follows including weighted average inputs used in calculating stock-based compensation: SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE Number of Number of Remaining Exercise Options Options Life in Intrinsic Price Outstanding Exercisable Term Years Value $ 1.01 515,000 515,000 10 7.93 8.03 $ 123,600 $ 1.25 890,000 14,167 10 9.81 9.92 - $ 1.37 200,000 30,000 10 9.63 - $ 1.50 2,195,943 2,195,943 10 8.53 - 3,800,943 2,755,110 $ 123,600 Warrants On June 12, 2019, as part of a financing, the Company issued warrants to purchase 113,637 3 three years On July 31, 2020, the Company completed the Somah Acquisition (see Note 4) whereas 10,000,000 3,000,000 5.00 0.6441 1,932,300 On September 25, 2020, the Company issued two warrants for services. The warrants were to purchase for 168,008 112,006 1.375 five years 0.9062 152,249 101,500 253,749 As of December 31, 2020, there are 3,393,651

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 11 - RELATED PARTY TRANSACTIONS As at September 30, 2021, the Company owed an aggregate of $ 638,530 Nil i. During the three months ended September 30, 2021, the Company entered into a promissory note agreement with a related party of the Company, for the total proceeds of $ 151,000 ii. During the nine months ended September 30, 2021, the Company entered into another promissory note agreement with a related party and shareholder of the Company, for the total proceeds of $ 215,000 iii. The Company received consulting services from a shareholder and consultant of the Company, and pursuant to the agreement incurred $ 30,000 270,000 90,000 2,530 272,530 Nil Additionally, as part of the Somah transaction in 2020 (Note 4), the Company recorded a prepaid royalty to the shareholders of Somahlution. The primary beneficial owner is Dr. Vithal Dhaduk, currently the Interim CEO, a director, and significant shareholder of the Company. As at September 30, 2021, the company had $ 340,969 344,321	NOTE 9 – RELATED PARTY TRANSACTIONS The Company has recorded a prepaid royalty to the shareholders of Somahlution, LLC in regard to the acquisition (see Note 5). The primary beneficial owner is Dr. Vithal Dhaduk, a director of the Company (appointed in 2021) and significant shareholder of the Company.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12 - COMMITMENTS AND CONTINGENCIES Legal Matters The Interim CEO of Marizyme, Dr. Vithal D. Dhaduk, also, a co-founder of Somahlution, LLC (“Dhaduk”), was the subject of a complaint filed in the United States District Court, Middle District of Pennsylvania, Civil Action No. 3:17 cv 02243 in December 2017 by Mukeshkkumar B. Patel (“Patel”), a former business partner of Dhaduk, which complaint made claims of breach of contract, promissory estoppel and unjust enrichment regarding a Memorandum of Understanding, dated July 16, 2015, between Patel and Dhaduk (“MOU”). The MOU provided that Dhaduk would pay Patel $9,450,000 as consideration for Patel’s agreement to, among other things, (i) exit certain legal entities that were purportedly jointly owned by certain affiliates of Dhaduk and Patel, including Somahlution LLC, and (ii) relinquish his ownership interests in such entities. On December 2, 2019, the court granted Patel’s motion for summary judgment on his breach of contract claim. The complaint was settled between Dhaduk and Patel in the nine months ended September 30, 2021, with no financial impact to the Company. Contingencies a. On July 13, 2019, the Company signed a consulting agreement, whereby the individual will receive: ● $ 30,000 ● Option to purchase 250,000 1.50 ● Royalties based on sales of Krillase assets, equal to 10 b. As part of the DuraGraft Acquisition, completed on July 31, 2020 (Note 4), the Company entered into the Agreement with Somah stockholders, whereby Marizyme is legally obligated to pay royalties on all net sales for Somahlution, Inc. The royalties associated with the Agreement are calculated as follows: Royalties on U.S. sales equal to: ● 5 ● 4 ● 2 Royalties on sales outside of the U.S.: ● 6 ● 4 ● 2 The royalties are in perpetuity. As at September 30, 2021, the Company had not earned any revenues from Krillase and did not have any sales of the DuraGraft products in U.S., therefore no royalties have been accrued or paid in the period. c. The Company has entered into arrangements for office and laboratories spaces. As at September 30, 2021, minimum lease payments in relation to lease commitments are payable as described in Note 5.	NOTE 6 – COMMITMENTS AND CONTINGENCIES Legal Matters From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of April 15, 2021, there were no pending or threatened lawsuits. Contingencies On July 13, 2019, the Company signed a consulting agreement with an individual to advise the Board of Directors. The individual receives $ 30,000 250,000 1.50 Royalties on sales equal to: 10 On December 15, 2019, the Company entered into the Agreement, as amended on March 31, 2020 and May 29, 2020, with Somah (see Note 5). The royalties associated with the Agreement will be calculated as follows: Royalties on U.S. sales equal to: 5 4 2 Royalties on sales outside of the U.S.: 6 4 2 The royalties are in perpetuity. As of December 31, 2020, there has been no revenue related to the above royalties. The Company, after the acquisition of Somah, has been leasing the office space on a month-to-month basis with a monthly rate of $ 10,701 Employment and Consulting Agreements On September 1, 2020, Bruce Harmon executed a consulting agreement and was named as chief financial officer. He is compensated $ 120,000 40,000 one year 120,000 1.25 On November 1, 2020, Dr. Neil J. Campbell executed an employment agreement and was named as chief executive officer, president and director. He is compensated $ 375,000 500,000 three years 1.25 On November 30, 2020, Dr. Steven Brooks executed a letter of understanding for employment as chief medical officer. On December 1, 2020, Dr. Donald Very executed a letter of understanding for employment as executive vice president. On January 16, 2020, Roger Schaller executed a letter of understanding for employment as executive vice president. Risks and Uncertainties The outbreak of the coronavirus (COVID-19) resulted in increased travel restrictions, and shutdown of businesses, which may cause slower recovery of the economy. We may experience impact from quarantines, market downturns and changes in customer behavior related to pandemic fears and impact on our workforce if the virus continues to spread. In addition, one or more of our customers, partners, service providers or suppliers may experience financial distress, delayed or defaults on payment, file for bankruptcy protection, sharp diminishing of business, or suffer disruptions in their business due to the outbreak. The extent to which the coronavirus impacts our results will depend on future developments and reactions throughout the world, which are highly uncertain and will include emerging information concerning the severity of the coronavirus and the actions taken by governments and private businesses to attempt to contain the coronavirus. It is likely to result in a potential material adverse impact on our business, results of operations and financial condition. Wider-spread COVID-19 globally could prolong the deterioration in economic conditions and could cause decreases in or delays in advertising spending and reduce and/or negatively impact our short-term ability to grow our revenues. Any decreased collectability of accounts receivable, bankruptcy of small and medium businesses, or early termination of agreements due to deterioration in economic conditions could negatively impact our results of operations.

SUBSEQUENT EVENT

SUBSEQUENT EVENT	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENT	NOTE 13 - SUBSEQUENT EVENT On November 1, 2021, Marizyme entered into a definitive arrangement agreement with Health Logic Interactive Inc. (“HLII”) pursuant to which the Company will acquire My Health Logic Inc., a wholly-owned subsidiary of HLII (the “Transaction”). The Transaction will be effected by way of a plan of arrangement under the Business Corporations Act (British Columbia). In connection with the plan of arrangement, Marizyme will issue an aggregate of 4,600,000 The acquisition is subject to, among other things, the approval of the Supreme Court of British Columbia, the approval of the NEX board of the TSX Venture Exchange, and requires the approval of at least two-thirds of the votes cast by HLII shareholders at the upcoming annual and special meeting of HLII shareholders. The Transaction is expected to close in December 2021.	NOTE 12 - SUBSEQUENT EVENTS SUBSEQUENT EVENT The Company has evaluated subsequent events through the date the consolidated financial statements were issued and filed with the Securities and Exchange Commission. The Company has determined that there are no other such events that warrant disclosure or recognition in the consolidated financial statements, except as stated herein. On January 1, 2021, the Company issued 7,500 three years 1.25 10 On January 12, 2021, the Company issued 20,000 three years 1.25 10 On January 13, 2021, the Board of Directors approved the Marizyme, Inc. 2021 Stock Incentive Plan (“SIP”). The SIP incorporates stock options issued prior to January 13, 2021. On January 16, 2021, the Company issued 40,000 three years 1.25 10 On January 29, 2021, the Company issued 40,000 three years 1.25 10 On January 31, 2021, the Company fully vested 50,000 On March 5, 2021, the Company modified the vesting of the common stock and stock options issued to Mr. Harmon. As of this date, all common stock was vested and 50% of the stock options were vested as of this date and the remaining 50% vest on October 22, 2021. See Note 10. On March 5, 2021, the Company issued 125,000 three years 1.25 10 On March 5, 2021, the Company issued 125,000 three years 1.25 10 On March 5, 2021, the Company issued 125,000 three year 1.25 10 On March 5, 2021, the Company issued 125,000 three years 1.25 10 On March 5, 2021, the Company issued 125,000 three years 1.25 10 On March 18, 2021, Dr. Campbell resigned from all positions. See Notes 1, 6 and 10 to the financial statements. On April 2, 2021, Dr. Satish Chandran was terminated from all positions.

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Overview Marizyme, Inc., a Nevada corporation formerly known as GBS Enterprises Incorporated (the “Company,” “we,” “our,” or “Marizyme”), conducted its primary business through its majority owned subsidiary, GBS Software AG (“GROUP”), a German-based public-company. By December 31, 2016, the Company had sold the controlling interest in GROUP and other subsidiaries, keeping only a minority interest in GROUP. On March 21, 2018, the Company formed a wholly owned subsidiary named Marizyme, Inc., a Nevada corporation, and merged with it, effectively changing the Company’s name to Marizyme, Inc. On June 1, 2018, the Company exchanged the shares of GROUP and all the intercompany assets and liabilities for 100 Beginning after the X-Assets share distribution, Marizyme refocused on the life sciences and began to seek technologies to acquire. On September 12, 2018, the Company consummated an asset acquisition with ACB Holding AB, Reg. No. 559119-5762, a Swedish corporation to acquire all right, title, and interest in their Krillase technology in exchange for 16.98 On December 15, 2019, the Company entered into a contingent asset purchase agreement (the “Agreement”), as amended on March 31, 2020 and May 29, 2020, with Somahlution, LLC, Somahlution, Inc., and Somaceutica, LLC, companies duly organized under the laws of Delaware (collectively, “Somah”) to acquire all of the assets and none of the liabilities of Somah (the “Acquisition”), including DuraGraft®, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. On July 30, 2020, the Company and Somah entered into Amendment No. 3 to the Agreement which finalized this Agreement. Pursuant to the terms of this amendment, it was agreed that, as part of the Acquisition, the Company would acquire the outstanding capital stock of Somahlution, Inc., held by Somahlution, LLC, rather than the assets of Somahlution, Inc. This change to the Agreement was made to accommodate the European Union (“EU”) requirements with respect to the future manufacturing under Somahlution, Inc. of CE marked products for sale in the EU. As part of the transaction, simultaneously with the closing, Marizyme, Inc. transferred the acquired assets to Somahlution, Inc. On September 25, 2020, the Company formed Somaceutica, Inc., a Florida corporation. On September 30, 2020, the Company formed Marizyme Sciences, Inc., a Florida corporation. The Company’s common stock, $ 0.001 Change in Management and the Board of Directors On September 1, 2020, Nicholas DeVito resigned as the Company’s interim Chief Executive Officer and Chief Financial Officer. On September 1, 2020, James Sapirstein, a Director of the Company, became the Company’s Interim Chief Executive Officer. On September 1, 2020, Bruce Harmon was appointed as the Company’s Chief Financial Officer. On November 1, 2020, Dr. Neil J. Campbell was appointed as the Company’s Chief Executive Officer, President, and Director. On November 1, 2020, James Sapirstein relinquished his role as interim Chief Executive Officer. On October 30, 2020, Dr. William Hearl was appointed as a Director on the Company’s board of directors. On December 1, 2020, Dr. Steven Brooks was appointed as the Company’s Chief Medical Officer and Executive Vice President of Medical and Regulatory Affairs. On December 2, 2020, Dr. Donald Very, Jr. was appointed as the Company’s Executive Vice President of Research and Development. On January 16, 2021, Roger Schaller was appointed as the Company Executive Vice President of Commercial Operations. On January 29, 2021, Amy Chandler was promoted to Executive Vice President of Regulatory Affairs and Quality Management Systems. On February 3, 2021, Julie Kampf was appointed as a Director on the Company’s board of directors. On February 22, 2021, Dr. Vithal Dhaduk was appointed as a Director on the Company’s board of directors. On March 18, 2021, Dr. Neil Campbell resigned as Chief Executive Officer, President and Director. On March 19, 2021, James Sapirstein was appointed as Interim Chief Executive Officer. On April 2, 2021, Dr. Satish Chandran was terminated as Chief Technology Officer.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 11 – INCOME TAXES As of December 31, 2020, and 2019, the Company has net operating loss carry forwards of $ 30,973,000 27,552,000 The Company’s tax expense differs from the “expected” tax expense for Federal income tax purposes (computed by applying the United States Federal tax rate of 21 SCHEDULE OF INCOME TAX EXPENSE December 31, December 31, 2020 2019 Tax expense (benefit) at the statutory rate $ (1,158,482 ) $ (222,188 ) Non-deductible items 385,216 - Deferred true-ups (56,746 ) - Change in valuation allowance 830,012 222,188 Total $ - $ - The tax effects of the temporary differences between reportable financial statement income and taxable income are recognized as deferred tax assets and liabilities. The tax years 2020 and 2019 remain open to examination by federal agencies and other jurisdictions in which it operates. The following is a reconciliation of the U.S. federal statutory rate to the effective income tax rates for the years ended December 31, 2020 and 2019: SCHEDULE OF EFFECTIVE INCOME TAX RATES December 31, December 31, 2020 2019 U.S. statutory federal rate 21.0 % 21.0 % Non-deductible / non-taxable items -6.5 % 0.0 % Deferred true-up -1.0 % 0.0 % Valuation allowance -13.5 % -21.0 % Total provision 0.0 % 0.0 % The tax effect of significant components of the Company’s deferred tax assets and liabilities at December 31, 2020 and 2019, are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES December 31, December 31, 2020 2019 Deferred tax assets: Net operating loss carryforward $ 6,504,000 $ 5,785,000 Lease liability 277,000 - Intangible assets 181,000 - Deferred tax liabilities: Fixed assets (277,000 ) - Total gross deferred tax assets 6,685,000 5,785,000 Less: Deferred tax asset valuation allowance (6,685,000 ) (5,785,000 ) Total net deferred taxes $ - $ - In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Because of the historical earnings history of the Company, the net deferred tax assets for 2020 and 2019 were fully offset by a 100% valuation allowance. The valuation allowance for the remaining net deferred tax assets was $ 6,685,000 5,785,000 On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The Company is currently evaluating the impact of the CARES Act, but at present does not expect that the NOL carryback provision of the CARES Act would result in a material cash benefit to them.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of the Company and its wholly owned subsidiaries, Somahlution, Inc. (“Somahlution”), Somaceutica, Inc. (“Somaceutica”) and Marizyme Sciences, Inc. (“Marizyme Sciences”). All intercompany transactions have been eliminated on consolidation. The accompanying unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q have been prepared in conformity with generally accepted accounting principles in the U.S. (“U.S. GAAP”). The unaudited condensed consolidated financial statements presented in this Quarterly Report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on April 15, 2021 (the “2020 Form 10-K”). The balance sheet as of December 31, 2020 was derived from audited consolidated financial statements included in the 2020 Form 10-K but does not include all disclosures required by U.S. GAAP for complete financial statements. The Company’s significant accounting policies are described in Note 3 to those consolidated financial statements. Interim results may not be indicative of the results that may be expected for the full year. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. The unaudited condensed consolidated financial statements reflect all adjustments which in the opinion of management are necessary for a fair statement of results of operations, financial condition, cash flows and stockholders’ equity for the periods presented. Except as otherwise disclosed, all such adjustments are of a normal recurring nature.
Use of Estimates	Use of Estimates The preparation of the unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the allocation of the purchase price in a business combination to the underlying assets and liabilities, recoverability of long-term assets including intangible assets and goodwill, amortization expense, valuation of warrants, stock-based compensation, derivative liabilities, contingent liabilities and deferred tax valuations.	Use of Estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the allocation of the purchase price in a business combination to the underlying assets and liabilities, allowance for doubtful accounts, recoverability of long-term assets including intangible assets and goodwill, amortization expense, inventory valuation, valuation of warrants, stock-based compensation, and deferred tax valuations.
Fair Value Measurements	Fair Value Measurements The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below: ● Level 1 - Quoted prices for identical assets or liabilities in active markets. ● Level 2 - Quoted prices for identical or similar assets and liabilities in markets that are not active; or other model-derived valuations whose inputs are directly or indirectly observable or whose significant value drivers are observable. ● Level 3 - Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable and for which assumptions are used based on management estimates. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. The carrying amounts of certain cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, and amounts due to related parties approximate fair value due to the short-term nature of these instruments. The contingent liabilities assumed on the acquisition of Somah (Note 4) consist of present values of royalty payments, performance warrants and pediatric voucher warrants, future rare pediatric voucher sales, and liquidation preference. Management measured these contingencies in accordance with Level 3 of the fair value hierarchy. i. The performance warrants and pediatric vouchers warrants liabilities were valued using a Monte Carlo simulation model utilizing the following weighted average assumptions: risk free rate of 1.19 %, expected volatility of 69.62 %, expected dividend of $ 0 , and expected life of 6.21 . For the three and nine months ended September 30, 2021, changes in these assumptions resulted in $ 574,000 1,870,000 decrease in fair value of these liabilities, respectively. At September 30, 2021 the fair market value of performance warrants and pediatric vouchers warrants liabilities was $ 2,899,000 ii. The present value of royalty payments was measured using the scenario-based methodology. In assessing the value attributed to the royalty payments, the estimated future cash flows were discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the revenue from net sales of the product. The cash flows derived from the Company’s fifteen-year strategic plan are based on managements’ expectations of market growth, industry reports and trends, and past performances. These projections are inherently uncertain due to the evolving impact of the COVID-19 pandemic. The discounted cash flow model included projections surrounding revenue, discount rates, and growth rates. The discount rates used to calculate the present value of royalty payments reflect specific risks of the Company and market conditions and the mid-range was estimated at 20.6 %. For the three and nine months ended September 30, 2021, changes in these assumptions resulted in $ 380,000 1,396,000 increase in fair value of these liabilities, respectively. At September 30, 2021 the fair market value of royalty payments was $ 3,582,000 iii. Rare pediatric voucher sales liability was valued based on the scenario-based methodology where the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset - 20.6%. For the three and nine months ended September 30, 2021, changes in these assumptions resulted in $ Nil 2,000 increase in fair value of this liability, respectively. At September 30, 2021 the fair market value of rare pediatric vouchers was $ 1,150,000 iv. The present value of liquidation preference liability, included in the contingent consideration, was determined using the Black-Scholes option pricing method and represents the fair value of the maximum payment amount according to the Agreement. The following assumptions were used in the Black-Scholes option pricing model: risk free rate of 0.21 %, expected volatility of 78.93 %, expected dividend of $ 0 , and expected life of 5 years. No changes to the fair value of liquidation preference liability were recorded in the three and nine months ended September 30, 2021. At September 30, 2021 the fair market value of liquidation preference was $ 1,823,000 The derivative liabilities consisted of optional and automatic conversion features and the share redemption feature attached to the convertible notes, issued pursuant to the Unit Purchase Agreement (Note 9). The Company has no financial assets measured at fair value on a recurring basis. None of the Company’s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented. Marizyme measures the following financial instruments at fair value on a recurring basis. As at September 30, 2021, the fair values of these financial instruments were as follows: SCHEDULE OF FAIR VALUES OF FINANCIAL INSTRUMENTS Fair Value Hierarchy September 30, 2021 Level 1 Level 2 Level 3 December 31, 2020 Liabilities Derivative liabilities $ - $ - $ 391,648 $ - Contingent liabilities - - 9,454,000 - Total $ - $ - $ 9,845,648 $ - The following table provides a rollforward of all liabilities measured at fair value using Level 3 significant unobservable inputs: RECONCILIATION OF LIABILITIES AT FAIR VALUE September 30, 2021 Contingent Liabilities Balance at December 31, 2020 - Derivative liabilities $ 391,648 Initial valuation of contingent liabilities in connection with the Somah acquisition 1 9,926,000 Change in fair value of contingent liabilities (472,000 ) Balance at September 30, 2021 $ 9,845,648 1 Measured as at Somah acquisition date of July 31, 2020, see Note 4.	Fair Value of Financial Instruments Fair Value Measurements The Company measures its financial assets and liabilities in accordance with FASB ASC 820 (the “Fair Value Topic”). For certain of our financial instruments, including cash, accounts payable, accrued expenses, and short-term loans the carrying amounts approximate fair value due to their short maturities. We follow accounting guidance for financial and non-financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. The Company had no
Fixed Assets	Fixed Assets Fixed assets are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method over the assets estimated useful life. Upon the sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in consolidated statements of operations. SCHEDULE OF USEFUL LIFE OF FIXED ASSETS Classification Estimated Useful Lives Equipment 5 to 7 years Furniture and fixtures 4 to 7 years	Fixed Assets Fixed assets are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method over the assets estimated useful life. Upon the sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in consolidated statements of operations. SCHEDULE OF USEFUL LIFE OF FIXED ASSETS Classification Estimated Useful Lives Equipment 5 7 Furniture and fixtures 4 7
Intangible Assets and Goodwill	Intangible Assets and Goodwill Intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. Intangible assets acquired as a result of an acquisition or in a business combination are measured at fair value at the acquisition date. The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized over the estimated useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimates being accounted for on a prospective basis. Goodwill represents the excess of the purchase price paid for the acquisition of subsidiaries over the fair value of the net assets acquired. Following the initial recognition, goodwill is measured at cost less any accumulated impairment losses.	Intangible Assets Intangible Assets and Goodwill Costs incurred to file patent applications and acquired intangibles are capitalized when the Company believes that there is a high likelihood that the patent will be issued and there will be future economic benefit associated with the patent. These costs will be amortized on a straight-line basis over a 20
In-Process Research and Development	In-Process Research and Development The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use. Intangible assets that do not have future alternative use are considered acquired in-process research and development. When the acquired in-process research and development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.	Research and Development In-Process Research and Development All research and development costs, payments to laboratories and research consultants are expensed when incurred.
Impairment of Long-lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets, including property, plant and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. No	Impairment of Long-lived Assets The Company follows ASC 360 for its long-lived assets. The Company’s long-lived assets, such as intellectual property, are required to be reviewed for impairment annually, or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The Company assesses the recoverability of its long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives. The Company determined that there were no
Segment Reporting	Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business as one	Segment Information Segment Reporting In accordance with the provisions of ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information,” the Company is required to report financial and descriptive information about its reportable operating segments. The Company has one
Net Income (Loss) per Share	Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. Dilutive common stock equivalents are comprised of unvested common stock, options and warrants. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities (warrants, stock options, and common shares subject to repurchase) would be antidilutive. The following is a reconciliation of basic and diluted earnings (loss) per common share for the years ended December 31, 2020 and 2019: SCHEDULE OF RECONCILIATION OF BASIC AND DILUTED EARNINGS (LOSS) For the Years Ended December 31, 2020 2019 Basic and diluted earnings per common share Numerator: Net loss available to common shareholders $ (5,845,053 ) $ (1,058,039 ) Denominator: Weighted average common shares outstanding 26,373,982 19,805,959 Basic and diluted loss per common share $ (0.22 ) $ (0.05 )	Net Income (Loss) per Share The Company computes basic and diluted income (loss) per share amounts pursuant to ASC 260 of the FASB Accounting Standards Codification. Basic loss per share is computed by dividing net loss available to common stockholders, by the weighted average number of shares of common stock outstanding during the period, excluding the effects of any potentially dilutive securities. Diluted loss per share is computed by dividing net loss available to common stockholders by the diluted weighted average number of shares of common stock during the period. The diluted weighted average number of common shares outstanding is the basic weighted number of shares adjusted as of the first day of the year for any potentially diluted debt or equity. The following is a reconciliation of basic and diluted earnings (loss) per common share for the years ended December 31, 2020 and 2019: SCHEDULE OF RECONCILIATION OF BASIC AND DILUTED EARNINGS (LOSS) For the Years Ended December 31, 2020 2019 Basic and diluted earnings per common share Numerator: Net loss available to common shareholders $ (5,845,053 ) $ (1,058,039 ) Denominator: Weighted average common shares outstanding 26,373,982 19,805,959 Basic and diluted loss per common share $ (0.22 ) $ (0.05 )
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards There are no recently adopted accounting standards and recent accounting standards not yet adopted that the Company believes will have a material impact on the Company’s unaudited condensed consolidated financial statements.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board or other standard setting bodies on the Company’s financial statements as well as material updates to previous assessments, if any, from the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. There were no new material accounting standards issued in the nine months ended September 30, 2021, that impacted the Company.
COVID-19	COVID-19 Since December 31, 2019, the outbreak of the novel strain of coronavirus, specifically identified as “COVID-19”, has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. These measures, which include the implementation of travel bans, self-imposed quarantine periods and physical distancing, have caused material disruptions to businesses globally resulting in an economic slowdown. Global equity markets have experienced significant volatility and weakness. The duration and impact of the COVID-19 outbreak is unknown at this time, as is the efficacy of the government and central bank interventions. It is not possible to reliably estimate the length and severity of these developments and the impact on the financial results and condition of the Company in future periods. Marizyme continues to maintain business continuity during the COVID-19 pandemic and takes its cues from the U.S. government and public health officials to keep employees and business partners safe and healthy. Although the financial results for three and nine months ended September 30, 2021 were not significantly impacted by COVID-19, Marizyme experienced decrease in sales due to a slow-down in the product manufacturing. During 2021, Marizyme’s business partners were focused on addressing specific manufacturing needs of the U.S. government in battling COVID-19 pandemic. Additionally, during 2021, demand for elective surgeries have decreased due to overloaded medical systems and potential risks related to patients’ recovery during the pandemic. The Company cannot predict the impact of the progression of COVID-19 on future results or the Company’s ability to raise capital due to a variety of factors, including but not limited to the continued good health of Company employees, the ability of suppliers to continue to operate and deliver, the ability of the Company to maintain operations, any further government and/or public actions taken in response to the pandemic and ultimately the length of the pandemic.
Basis of Presentation		Basis of Presentation The Company follows the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP).
Principles of Consolidation		Principles of Consolidation The accompanying consolidated financial statements include all of the accounts of the Company and its wholly owned subsidiaries, Somahlution, Inc. (“Somahlution”), Somaceutica, Inc. (“Somaceutica”) and Marizyme Sciences, Inc. (“Marizyme Sciences”). All significant intercompany balances and transactions have been eliminated.
Business Combinations		Business Combinations The Company accounts for business acquisitions using the acquisition method of accounting based on Accounting Standards Codification (“ASC”) 805 — Business Combinations, which requires recognition and measurement of all identifiable assets acquired and liabilities assumed at their fair value as of the date control is obtained. The Company determines the fair value of assets acquired and liabilities assumed based upon its best estimates of the acquisition-date fair value of assets acquired and liabilities assumed in the acquisition. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Subsequent adjustments to fair value of any contingent consideration are recorded to the Company’s consolidated statements of operations.
Stock-Based Compensation		Stock-Based Compensation Stock-based compensation expense is recorded in accordance with FASB ASC Topic 718, Compensation – Stock Compensation, for stock and stock options awarded in return for services rendered. The expense is measured at the grant-date fair value of the award and recognized as compensation expense on a straight-line basis over the service period, which is the vesting period. The Company estimates forfeitures that it expects will occur and records expense based upon the number of awards expected to vest. The fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model.
Cash Equivalents		Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. At December 31, 2020 and 2019, the Company had no
Reclassifications		Reclassifications Certain amounts in the prior year’s consolidated financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported. The reclassifications were for the Statement of Operation which combined its expenses into two categories whereas, for comparison purposes for the years ended December 31, 2020 to December 31, 2019, professional fees and stock-based compensation was segregated.
Allowance for Doubtful Accounts		Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure trade and notes receivable are not overstated due to non-collectability. The Company’s allowance is based on a variety of factors, including age of the receivable, significant one-time events, historical experience, and other risk considerations. The Company did no no
Inventory		Inventory Inventory consisted of primarily finished goods and is valued at the lower of cost or net realizable value. Inventory is held in a third-party warehouse in foreign countries. Cost is determined using the FIFO method. The Company decreases the value of inventory for estimated obsolescence equal to the difference between the cost of inventory and the estimated market value, based upon an aging analysis of the inventory on hand, specifically known inventory-related risks, and assumptions about future demand and market conditions. The Company has determined that no
Revenue Recognition		Revenue Recognition We recognize revenue under Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, (“ASC 606”). The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. We only apply the five-step model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the goods and services transferred to the customer. The following five steps are applied to achieve that core principle: Step 1: Identify the contract with the customer Step 2: Identify the performance obligations in the contract Step 3: Determine the transaction price Step 4: Allocate the transaction price to the performance obligations in the contract Step 5: Recognize revenue when the company satisfies a performance obligation We have identified one performance obligation which is related to our DuraGraft product sales. For our Distribution Partner channel, we recognize revenue for product sales at the time of delivery of the product to our Distribution Partner (customer). The customer is invoiced, and Payment Terms are Net 30. As our products have an expiration date, if a product expires, we will replace the product at no charge. Revenue disaggregation for year ended December 31, 2020 amount to $ 71,610 23,080 63,110 39,336 In the transaction that acquired the assets of Somahlution, LLC, the Company determined that the CE mark for Europe must be in Marizyme, Inc. in order for Somahlution, Inc. to bill revenue and receive the payments accordingly. The Company has filed in Europe for the CE mark to be in Marizyme, Inc. but, until the time it is approved by the Notified Body, BSI (British Standards Institution), which is projected for May 2021, Somahlution, LLC provides the billing and receiver of funds. On a periodical basis, the cash received is transferred to Somahlution, Inc.
Direct Cost of Revenue		Direct Cost of Revenue Cost of sales includes the actual cost of merchandise sold; the cost of transportation of merchandise from our third-party vendor to our distributer.
Income Taxes		Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and loss carryforwards and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rules on deferred tax assets and liabilities is recognized in operations in the year of change. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of December 31, 2020 and 2019. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as interest expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the years ended December 31, 2020 and 2019.
Effect of Recent Accounting Pronouncements		Effect of Recent Accounting Pronouncements Accounting Standards Adopted During the Year Ended December 31, 2020 The Company adopted Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), as of January 1, 2020, using the modified retrospective approach. The modified retrospective approach provides a method for recording existing leases at the application date. In addition, the Company elected the available practical expedients permitted under the transaction guidance within the new standard. The most significant impact from the adoption of the new standard was the recognition of operating lease right-of-use assets and operating lease liabilities. The Company entered into a new lease in December 2020 which resulted in the recording of additional lease assets and liabilities with a balance of $ 1,317,830 Recently Issued Accounting Standards Not Yet Adopted The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its consolidated financial statements.
Concentration of Credit Risk		Concentration of Credit Risk The Company places its temporary cash investments with financial institutions insured by the FDIC. The Company has amounts over insured limits. Amounts on deposit may at times exceed the FDIC insurance limit. The Company has not experienced any losses in such accounts.
Customer Concentrations		Customer Concentrations For the year ended December 31, 2020, four customers made up 100 100 no

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
SCHEDULE OF FAIR VALUES OF FINANCIAL INSTRUMENTS	Marizyme measures the following financial instruments at fair value on a recurring basis. As at September 30, 2021, the fair values of these financial instruments were as follows: SCHEDULE OF FAIR VALUES OF FINANCIAL INSTRUMENTS Fair Value Hierarchy September 30, 2021 Level 1 Level 2 Level 3 December 31, 2020 Liabilities Derivative liabilities $ - $ - $ 391,648 $ - Contingent liabilities - - 9,454,000 - Total $ - $ - $ 9,845,648 $ -
RECONCILIATION OF LIABILITIES AT FAIR VALUE	The following table provides a rollforward of all liabilities measured at fair value using Level 3 significant unobservable inputs: RECONCILIATION OF LIABILITIES AT FAIR VALUE September 30, 2021 Contingent Liabilities Balance at December 31, 2020 - Derivative liabilities $ 391,648 Initial valuation of contingent liabilities in connection with the Somah acquisition 1 9,926,000 Change in fair value of contingent liabilities (472,000 ) Balance at September 30, 2021 $ 9,845,648 1 Measured as at Somah acquisition date of July 31, 2020, see Note 4.
SCHEDULE OF USEFUL LIFE OF FIXED ASSETS	SCHEDULE OF USEFUL LIFE OF FIXED ASSETS Classification Estimated Useful Lives Equipment 5 to 7 years Furniture and fixtures 4 to 7 years	SCHEDULE OF USEFUL LIFE OF FIXED ASSETS Classification Estimated Useful Lives Equipment 5 7 Furniture and fixtures 4 7
SCHEDULE OF RECONCILIATION OF BASIC AND DILUTED EARNINGS (LOSS)	The following is a reconciliation of basic and diluted earnings (loss) per common share for the years ended December 31, 2020 and 2019: SCHEDULE OF RECONCILIATION OF BASIC AND DILUTED EARNINGS (LOSS) For the Years Ended December 31, 2020 2019 Basic and diluted earnings per common share Numerator: Net loss available to common shareholders $ (5,845,053 ) $ (1,058,039 ) Denominator: Weighted average common shares outstanding 26,373,982 19,805,959 Basic and diluted loss per common share $ (0.22 ) $ (0.05 )	The following is a reconciliation of basic and diluted earnings (loss) per common share for the years ended December 31, 2020 and 2019: SCHEDULE OF RECONCILIATION OF BASIC AND DILUTED EARNINGS (LOSS) For the Years Ended December 31, 2020 2019 Basic and diluted earnings per common share Numerator: Net loss available to common shareholders $ (5,845,053 ) $ (1,058,039 ) Denominator: Weighted average common shares outstanding 26,373,982 19,805,959 Basic and diluted loss per common share $ (0.22 ) $ (0.05 )

ACQUISITIONS (Tables)

ACQUISITIONS (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Business Combination and Asset Acquisition [Abstract]
SCHEDULE OF PRELIMINARY ALLOCATION OF CONSIDERATION	Details of the carrying amount and the fair value of identifiable assets and liabilities acquired and purchase consideration paid are as follows: SCHEDULE OF PRELIMINARY ALLOCATION OF CONSIDERATION Consideration Common shares $ 12,500,000 Warrants 1,200,000 Contingent consideration 1 9,926,000 Total consideration $ 23,626,000 Fair value of identifiable assets acquired, and liabilities assumed Net working capital $ 30,908 Property, plant, and equipment 9,092 Receivables - Inventory - Intangible assets 18,170,000 Goodwill 5,416,000 Total identifiable assets $ 23,626,000 1 Contingent consideration, for the purposes of the final allocation of the purchase price consideration, was measured as at the date of Somah acquisition - July 31, 2020. During the nine months ended September 30, 2021, the fair market value of the contingent liabilities, measured in accordance with Level 3 of the fair value hierarchy, has decreased by $ 472,000	SCHEDULE OF PRELIMINARY ALLOCATION OF CONSIDERATION Consideration given: Common stock shares given $ 12,500,000 Warrants given 1,932,300 Total consideration given $ 14,432,300 Fair value of identifiable assets acquired, and liabilities assumed: Receivables $ 45,845 Inventory 229,635 Fixed assets 9,092 Intangible assets 14,147,728 Total identifiable net assets $ 14,432,300

LEASES (Tables)

LEASES (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Leases
SCHEDULE OF RIGHT-OF-USE ASSET AND RELATED LEASE LIABILITY	The following table summarizes supplemental balance sheet information related to the operating lease as of September 30, 2021 and December 31, 2020. SCHEDULE OF RIGHT-OF-USE ASSET AND RELATED LEASE LIABILITY September 30, 2021 December 31, 2020 Right-of-use asset $ 1,163,159 $ 1,317,830 Operating lease liabilities, current $ 260,106 $ 243,292 Operating lease liabilities, non-current 941,732 1,074,538 Total operating lease liabilities $ 1,201,838 $ 1,317,830	SCHEDULE OF RIGHT-OF-USE ASSET AND RELATED LEASE LIABILITY December 31, 2020 2019 Right-of-use asset $ 1,317,830 $ - Total lease liability $ 1,317,830 $ - Less: Current portion 243,292 - Lease liability, net of current portion $ 1,074,538 $ -
SCHEDULE OF MATURITIES OF LEASE LIABILITIES	As at September 30, 2021, the maturities of the lease liabilities for the periods ended December 31 were as follows: SCHEDULE OF MATURITIES OF LEASE LIABILITIES 2021 $ 52,249 2022 277,142 2023 277,142 2024 277,142 2025 277,142 2025 Thereafter 130,950 Total lease payments 1,291,767 Total lease payments 1,291,767 Less: present value discount (89,929 ) Total $ 1,201,838	The maturities of the lease liabilities are as follows as of December 31, 2020: SCHEDULE OF MATURITIES OF LEASE LIABILITIES 2021 $ 208,997 2022 277,142 2023 277,142 2024 277,142 2025 277,142 Thereafter 130,950 Total lease payments 1,470,148 Less: Present value discount (152,318 ) Total $ 1,317,830

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY PLANT & EQUIPMENT	Property, plant and equipment, summarized by major category, stated at cost, less accumulated depreciation at September 30, 2021 and December 31, 2020 consisted of the following: SCHEDULE OF PROPERTY PLANT & EQUIPMENT September 30, 2021 December 31, 2020 Furniture and equipment $ 701 $ 701 Computer related 7,220 7,220 Machinery and equipment 1,171 1,171 Total $ 9,092 $ 9,092 Less: accumulated amortization (7,819 ) (1,970 ) Property, plant and equipment, net $ 1,273 $ 7,122	Fixed assets, stated at cost, less accumulated depreciation at December 31, 2020 and 2019 consisted of the following: SCHEDULE OF PROPERTY PLANT & EQUIPMENT 2020 2019 December 31, 2020 2019 Furniture and equipment $ 701 $ - Computer related 7,220 - Machinery and equipment 1,171 - Total 9,092 - Less: accumulation depreciation (1,970 ) - Property and equipment, net $ 7,122 $ -

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
SUMMARY OF INTANGIBLE ASSETS AMORTIZATION EXPENSE	As part of Somah acquisition (Note 4), Marizyme purchased $ 18,170,000 of intangible assets related to the DuraGraft® technology. SUMMARY OF INTANGIBLE ASSETS AMORTIZATION EXPENSE September 30, 2021 December 31, 2020 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Krillase intangible assets $ 28,600,000 $ - $ 28,600,000 $ 28,600,000 $ - $ 28,600,000 DuraGraft patent 5,256,000 (471,691 ) 4,784,309 14,147,729 (589,489 ) 13,558,240 Distributor relationship 308,000 (35,933 ) 272,067 - - - IPR&D - Cyto Protectant Life Sciences 12,606,000 - 12,606,000 - - - Patents in process 122,745 - 122,745 119,971 - 119,971 Total intangibles $ 46,892,745 $ (507,624 ) $ 46,385,121 $ 42,867,700 $ (589,489 ) $ 42,278,211	SUMMARY OF INTANGIBLE ASSETS AMORTIZATION EXPENSE December 31, 2020 December 31, 2019 Gross Net Gross Net Carrying Accumulated Carrying Carrying Accumulated Carrying Amount Amortization Amount Amount Amortization Amount Krillase - Patents, Patent Applications, Research and Development, Clinical Trials, Developed Technology $ 28,600,000 $ - $ 28,600,000 $ 28,600,000 $ - $ 28,600,000 DuraGraft - Patents, Patent Applications, Research and Development, Clinical Trials, Developed Technology 14,147,729 (589,489 ) 13,558,240 - - - Patents in process 119,971 - 119,971 13,000 13,000 Total Intangibles $ 42,867,700 $ (589,489 ) $ 42,278,211 $ 28,613,000 $ - $ 28,613,000
SCHEDULE OF INTANGIBLE ASSETS	SCHEDULE OF INTANGIBLE ASSETS Balance, December 31, 2019 $ 28,613,000 Acquired in asset purchase agreement 14,147,729 Additions 106,971 Amortization expense (589,489 ) Accumulated amortization (589,489) Balance, December 31, 2020 42,278,211 Acquired in Somah Transaction 1 4,022,271 Additions 2,775 Amortization expense 1 81,864 Balance, September 30, 2021 $ 46,385,121 1 To account for Somah Transaction measurement period adjustments, the Company restated the Quarterly Report on Form 10-Q for the three and six month ended June 30, 2021, originally filed on August 23, 2021. As a result of the restatement, the value of DuraGraft intangibles purchased with the Somah Transaction increased by $ 4,022,271 898,026	SCHEDULE OF INTANGIBLE ASSETS Balance, December 31, 2019 $ 28,613,000 Acquired in asset purchase agreement 14,147,729 Additions 106,971 Accumulated amortization (589,489 ) Balance, December 31, 2020 $ 42,278,211

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	Accounts payable and accrued expenses, summarized by major category, as of September 30, 2021 and December 31, 2020 consists of the following: SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES September 30, 2021 December 31, 2020 Trade accounts payable $ 1,117,517 $ 325,830 Accrued expenses 180,846 21,555 Accrued compensation expenses 98,582 130,718 Total accounts payable and accrued expenses $ 1,396,945 $ 478,103

CONVERTIBLE PROMISSORY NOTES _2

CONVERTIBLE PROMISSORY NOTES AND WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
SCHEDULE OF CONVERTIBLE NOTES	SCHEDULE OF CONVERTIBLE NOTES September 30, 2021 December 31, 2020 Convertible notes issued $ 1,174,945 $ Issuance costs (105,745 ) - Debt discount (964,153 ) - Debt accretion 74,410 - Convertible notes, net of debt discount $ 179,457 $ -

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Equity [Abstract]
SCHEDULE OF SHARE BASED STOCK OPTION VALUATION ASSUMPTIONS	SCHEDULE OF SHARE BASED STOCK OPTION VALUATION ASSUMPTIONS 2021 2020 Risk-free interest rate 0.69 % 0.93 % Volatility 232.69 % 241.88 % Exercise price $ 1.25 $ 1.37 Dividend yield 0 % 0 % Forfeiture rate 0 % 0 % Expected life (years) 3 10
SCHEDULE OF STOCK OPTION ACTIVITY	The summary of option activity for the nine months ended September 30, 2021 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY Number of Weighted Weighted Total Intrinsic Outstanding at December 31, 2019 2,715,000 $ 1.50 9.48 $ N/A 1 Granted 1,340,000 1.25 Exercised (254,057 ) 1.02 Outstanding at December 31, 2020 3,800,943 $ 1.36 8.82 $ 123,600 Granted 732,500 1.25 Forfeited (760,626 ) 1.25 Outstanding at September 30, 2021 3,772,817 $ 1.37 8.13 $ 97,850 Exercisable at September 30, 2021 3,074,476 $ 1.39 3.77 $ 97,850 1	The summary of option activity for the years ended December 31, 2020 and 2019 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY Weighted Weighted Average Average Total Number of Exercise Contractual Intrinsic Options Price Life Value Outstanding at December 31, 2018 265,000 $ 1.50 Granted 2,450,000 $ 1.01 Exercised - $ - Forfeited - $ - Outstanding at December 31, 2019 2,715,000 $ 1.50 Granted 1,340,000 $ 1.25 Exercised (254,057 ) $ 1.02 Forfeited - $ - Outstanding at December 31, 2020 3,800,943 $ 1.36 8.82 $ 123,600 Exercisable at December 31, 2020 2,755,110 $ 1.40
SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE	SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE Number of Number of Remaining Exercise Options Options Life in Intrinsic Price Outstanding Exercisable Term Years Value $ 1.01 515,000 515,000 10 7.93 8.03 $ 123,600 $ 1.25 890,000 14,167 10 9.81 9.92 - $ 1.37 200,000 30,000 10 9.63 - $ 1.50 2,195,943 2,195,943 10 8.53 - 3,800,943 2,755,110 $ 123,600	SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE Number of Number of Remaining Exercise Options Options Life in Intrinsic Price Outstanding Exercisable Term Years Value $ 1.01 515,000 515,000 10 7.93 8.03 $ 123,600 $ 1.25 890,000 14,167 10 9.81 9.92 - $ 1.37 200,000 30,000 10 9.63 - $ 1.50 2,195,943 2,195,943 10 8.53 - 3,800,943 2,755,110 $ 123,600
SCHEDULE OF OPTIONS OUTSTANDING AND ISSUED	SCHEDULE OF OPTIONS OUTSTANDING AND ISSUED Number Weighted Average December 30, 2019 113,637 $ 3.00 Issued on Somah acquisition (Note 4) 3,000,000 5.00 Issued 280,014 1.38 December 30, 2020 3,393,651 $ 2.13 Issued 1,044,396 2.25 September 30, 2021 4,438,047 $ 2.16

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
SCHEDULE OF INCOME TAX EXPENSE	The Company’s tax expense differs from the “expected” tax expense for Federal income tax purposes (computed by applying the United States Federal tax rate of 21 SCHEDULE OF INCOME TAX EXPENSE December 31, December 31, 2020 2019 Tax expense (benefit) at the statutory rate $ (1,158,482 ) $ (222,188 ) Non-deductible items 385,216 - Deferred true-ups (56,746 ) - Change in valuation allowance 830,012 222,188 Total $ - $ -
SCHEDULE OF EFFECTIVE INCOME TAX RATES	The following is a reconciliation of the U.S. federal statutory rate to the effective income tax rates for the years ended December 31, 2020 and 2019: SCHEDULE OF EFFECTIVE INCOME TAX RATES December 31, December 31, 2020 2019 U.S. statutory federal rate 21.0 % 21.0 % Non-deductible / non-taxable items -6.5 % 0.0 % Deferred true-up -1.0 % 0.0 % Valuation allowance -13.5 % -21.0 % Total provision 0.0 % 0.0 %
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES	The tax effect of significant components of the Company’s deferred tax assets and liabilities at December 31, 2020 and 2019, are as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES December 31, December 31, 2020 2019 Deferred tax assets: Net operating loss carryforward $ 6,504,000 $ 5,785,000 Lease liability 277,000 - Intangible assets 181,000 - Deferred tax liabilities: Fixed assets (277,000 ) - Total gross deferred tax assets 6,685,000 5,785,000 Less: Deferred tax asset valuation allowance (6,685,000 ) (5,785,000 ) Total net deferred taxes $ - $ -

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 42,308,427						$ 42,308,427		$ 36,825,634	$ 30,980,581
Working capital	2,132,227						2,132,227
Cash	16,673						16,673
Net loss	$ 1,631,999	$ 1,638,928	$ 2,211,866	$ 2,065,043	$ 434,911	$ 471,370	5,482,793	$ 2,971,324	5,845,053	1,058,039
Cash used in operating activities							$ 4,313,038	$ 948,305	3,223,836	$ 112,014
Working capital surplus									$ 2,384,682

SCHEDULE OF FAIR VALUES OF FINA

SCHEDULE OF FAIR VALUES OF FINANCIAL INSTRUMENTS (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Derivative liabilities
Contingent liabilities	$ 9,454,000
Total
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liabilities
Contingent liabilities
Total
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liabilities
Contingent liabilities
Total
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liabilities	391,648
Contingent liabilities	9,454,000
Total	$ 9,845,648

RECONCILIATION OF LIABILITIES A

RECONCILIATION OF LIABILITIES AT FAIR VALUE (Details) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Contingent liabilities beginning balance
Derivative Liability
Change in fair value of contingent liabilities		$ (194,000)		(472,000)
Contingent liabilities ending balance		9,454,000		9,454,000
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative Liability		391,648		391,648
Contingent liabilities ending balance		9,454,000		9,454,000
Fair Value, Inputs, Level 3 [Member] | Contingent Liability [Member]
Defined Benefit Plan Disclosure [Line Items]
Contingent liabilities beginning balance
Derivative Liability		391,648		391,648
Valuation of contingent liabilites assumed	[1]			9,926,000
Change in fair value of contingent liabilities				(472,000)
Contingent liabilities ending balance		$ 9,845,648		$ 9,845,648
[1]	Measured as at Somah acquisition date of July 31, 2020, see Note 4.

SCHEDULE OF USEFUL LIFE OF FIXE

SCHEDULE OF USEFUL LIFE OF FIXED ASSETS (Details)	12 Months Ended
	Dec. 31, 2020
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	4 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years

SCHEDULE OF RECONCILIATION OF B

SCHEDULE OF RECONCILIATION OF BASIC AND DILUTED EARNINGS (LOSS) (Details) - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Basic and diluted earnings per common share: Net loss available to common shareholders	$ (1,631,999)	$ (1,638,928)	$ (2,211,866)	$ (2,065,043)	$ (434,911)	$ (471,370)	$ (5,482,793)	$ (2,971,324)	$ (5,845,053)	$ (1,058,039)
Basic and diluted earnings per common share: Weighted average common shares outstanding	35,928,188			29,288,226			35,928,188	23,161,329	26,373,982	19,805,959
Basic and diluted earnings per common share: Basic and diluted loss per common share	$ (0.05)			$ (0.07)			$ (0.15)	$ (0.13)	$ (0.22)	$ (0.05)

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)Segment	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)Segment	Dec. 31, 2019USD ($)Segment
Product Information [Line Items]
Increase (Decrease) in Derivative Liabilities					$ 2,000
Fair market value of performance warrants	$ 2,899,000				571,807
Fair market value of royalty payments		$ 3,582,000
Fair market value of rare pediatric vouchers	1,150,000	1,150,000	1,150,000		1,150,000
Fair market value of liquidation preference	1,823,000	1,823,000	1,823,000		1,823,000
Impairments of long-lived assets					$ 0		$ 0	$ 0
Number of operating segment | Segment					1		1	1
Cash equivalents							$ 0	$ 0
Allowance for doubtful accounts							0	0
Bad debt expense							0	0
Inventory reserve							0	0
Assets or liabilities measured at fair value on a recurring basis							$ 0	0
Intangible assets useful life							20 years
Revenue			37,215	$ 124,985	$ 271,952	$ 124,985	$ 197,136
Operating Lease, Right-of-Use Asset	$ 1,163,159	$ 1,163,159	1,163,159		1,163,159		$ 1,317,830
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Four Customer [Member]
Product Information [Line Items]
Concentration risk, percentage							100.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | No Customer [Member]
Product Information [Line Items]
Concentration risk, percentage								0.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Three Customer [Member]
Product Information [Line Items]
Concentration risk, percentage							100.00%
SPAIN
Product Information [Line Items]
Revenue							$ 71,610
SINGAPORE
Product Information [Line Items]
Revenue							23,080
AUSTRIA
Product Information [Line Items]
Revenue							63,110
SWITZERLAND
Product Information [Line Items]
Revenue							$ 39,336
Royalty [Member]
Product Information [Line Items]
Increase (Decrease) in Derivative Liabilities			380,000		1,396,000
Monte Carlo Simulation Model [Member]
Product Information [Line Items]
Increase (Decrease) in Derivative Liabilities			$ 574,000		$ 1,870,000
Fair Value, Inputs, Level 3 [Member]
Product Information [Line Items]
Derivative liability measurement input term	6 years 2 months 15 days	6 years 2 months 15 days	6 years 2 months 15 days		6 years 2 months 15 days
Measurement Input, Risk Free Interest Rate [Member]
Product Information [Line Items]
Derivative Liability, Measurement Input	0.21	0.21	0.21		0.21
Measurement Input, Risk Free Interest Rate [Member] | Fair Value, Inputs, Level 3 [Member]
Product Information [Line Items]
Derivative Liability, Measurement Input	1.19	1.19	1.19		1.19
Measurement Input, Price Volatility [Member]
Product Information [Line Items]
Derivative Liability, Measurement Input	78.93	78.93	78.93		78.93
Measurement Input, Price Volatility [Member] | Fair Value, Inputs, Level 3 [Member]
Product Information [Line Items]
Derivative Liability, Measurement Input	69.62	69.62	69.62		69.62
Measurement Input, Expected Dividend Rate [Member]
Product Information [Line Items]
Derivative Liability, Measurement Input	0	0	0		0
Measurement Input, Expected Dividend Rate [Member] | Fair Value, Inputs, Level 3 [Member]
Product Information [Line Items]
Derivative Liability, Measurement Input	0	0	0		0
Measurement Input, Discount Rate [Member]
Product Information [Line Items]
Derivative Liability, Measurement Input	20.6	20.6	20.6		20.6
Measurement Input, Expected Term [Member]
Product Information [Line Items]
Derivative liability measurement input term	5 years	5 years	5 years		5 years

SCHEDULE OF PRELIMINARY ALLOCAT

SCHEDULE OF PRELIMINARY ALLOCATION OF CONSIDERATION (Details) - USD ($)		9 Months Ended	12 Months Ended
		Sep. 30, 2021	Dec. 31, 2020
Business Combination and Asset Acquisition [Abstract]
Common stock shares given		$ 12,500,000	$ 12,500,000
Warrants given		1,200,000	1,932,300
Contingent consideration	[1]	9,926,000
Total consideration given		23,626,000	14,432,300
Net working capital		30,908
Fixed assets		9,092	9,092
Receivables			45,845
Inventory			229,635
Intangible assets		18,170,000	14,147,728
Goodwill		5,416,000
Total identifiable net assets		$ 23,626,000	$ 14,432,300
[1]	Contingent consideration, for the purposes of the final allocation of the purchase price consideration, was measured as at the date of Somah acquisition - July 31, 2020. During the nine months ended September 30, 2021, the fair market value of the contingent liabilities, measured in accordance with Level 3 of the fair value hierarchy, has decreased by $ 472,000

SCHEDULE OF PRELIMINARY ALLOC_2

SCHEDULE OF PRELIMINARY ALLOCATION OF CONSIDERATION (Details) (Parenthetical)	9 Months Ended
	Sep. 30, 2021USD ($)
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Decrease in contingent liabilities	$ 472,000

ACQUISITIONS (Details Narrative

ACQUISITIONS (Details Narrative) - USD ($)	Sep. 25, 2020	Aug. 03, 2020	Jul. 31, 2020	Sep. 12, 2018	May 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Prepaid royalties, non-current						$ 340,969			$ 340,969		$ 344,321
Warrant, shares						250,000			250,000
Revenue, remaining performance obligation, percentage						6.00%			6.00%
Additional revenues									$ 50,000,000
Additional revenue									200,000,000
Warrants amount						$ 20,000,000			$ 20,000,000
Intangible assets useful life											20 years
Weighted average cost of capital percentage						33.80%			33.80%
Acquisitions, value								$ 12,500,000			$ 12,500,000
Legal and filing fees											17,801
Prepaid royalties, non-current											$ 344,321
Sale of common stock, shares					29,978
Shares issues at common stock value								6,275,064				125,000
Royalties percentage									10.00%		10.00%
Net sales						$ 37,215		124,985	$ 271,952	$ 124,985	$ 197,136
Percentage of allocation to intangible assets											100.00%
Amortization expense						$ 108,777	$ 4,022,271	$ 341,270	326,331	$ 341,270	$ 589,489
Consideration transferred amount									$ 23,626,000		14,432,300
Mukeshkkumar B Patel [Member]
Business Acquisition [Line Items]
Consideration transferred amount											9,450,000
Dura Graft Patents [Member]
Business Acquisition [Line Items]
Intangible assets useful life									13 years
Distribution Rights [Member]
Business Acquisition [Line Items]
Intangible assets useful life									10 years
Maximum [Member]
Business Acquisition [Line Items]
Additional revenue									$ 50,000,000
Revenue recognized									$ 200,000,000
Royalty [Member]
Business Acquisition [Line Items]
Revenue, remaining performance obligation, percentage						5.00%			5.00%
Additional revenue									$ 50,000,000
Royalty [Member] | Minimum [Member]
Business Acquisition [Line Items]
Revenue, remaining performance obligation, percentage						4.00%			4.00%
Royalty [Member] | Maximum [Member]
Business Acquisition [Line Items]
Revenue, remaining performance obligation, percentage						2.00%			2.00%
Restricted Stock [Member]
Business Acquisition [Line Items]
Stock Issued During Period, Shares, Issued for Services									10,000,000
Warrant, shares						3,000,000			3,000,000
Warrant, per shares						$ 5			$ 5
Warrant, term						5 years			5 years
Restricted Stock [Member] | Performance Warrants [Member]
Business Acquisition [Line Items]
Warrant, shares						4,000,000			4,000,000
Somah [Member]
Business Acquisition [Line Items]
Prepaid royalties, non-current											344,321
Warrant, shares			3,000,000
Warrant, per shares			$ 5
Warrant, term			5 years
Business combination, description			The Company compensated the Somah stockholders as follows: (1) 10,000,000 shares of common stock valued at $1.25 per share (the Company’s stock is thinly traded therefore the value per share was determined by the funding completed on August 3, 2020 which sold 4,610,064 shares of common stock at $1.25 per share, which was the first tranche of a total funding of $7,000,240 (5,600,272 shares, August 3, 2020 and September 25, 2020) which all stock was sold at $1.25 per share); (2) 3,000,000 warrants with a strike price of $5.00 per share and a term of five years; and (3) royalties on all net sales for Somahlution, Inc. of 6% on the first $50 million of net sales, 4% for greater than $50 million up to $200 million, and 2% for greater than $200 million.
Number of shares issues at common stock	5,600,272	5,600,272	10,000,000
Shares issued, price per share	$ 1.25	$ 1.25	$ 1.25
Sale of common stock, shares		4,610,064
Shares issues at common stock value	$ 7,000,240	$ 7,000,240
Krillase Technology [Member]
Business Acquisition [Line Items]
Issuance of common stock for acquisition, shares				16,980,000
Acquisitions, value				$ 28,600,000
Legal and filing fees											$ 17,801
Somahlution Inc [Member] | Sales [Member]
Business Acquisition [Line Items]
Royalties percentage			6.00%
Net sales			$ 50,000,000
Somahlution Inc [Member] | Minimum [Member] | One Sales [Member]
Business Acquisition [Line Items]
Royalties percentage			4.00%
Net sales			$ 50,000,000
Somahlution Inc [Member] | Maximum [Member] | One Sales [Member]
Business Acquisition [Line Items]
Royalties percentage			4.00%
Net sales			$ 200,000,000
Somahlution Inc [Member] | Maximum [Member] | Two Sales [Member]
Business Acquisition [Line Items]
Royalties percentage			2.00%
Net sales			$ 200,000,000

SCHEDULE OF RIGHT-OF-USE ASSET

SCHEDULE OF RIGHT-OF-USE ASSET AND RELATED LEASE LIABILITY (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Leases
Right-of-use asset	$ 1,163,159	$ 1,317,830
Less: Current portion	260,106	243,292
Lease liability, net of current portion	941,732	1,074,538
Total lease liability	$ 1,201,838	$ 1,317,830

SCHEDULE OF MATURITIES OF LEASE

SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Leases
2021	$ 52,249
2021	277,142	$ 208,997
2022	277,142	277,142
2023	277,142	277,142
2024	277,142	277,142
2025		277,142
Thereafter	130,950	130,950
Total lease payments	1,291,767	1,470,148
Less: Present value discount	(89,929)	(152,318)
Total	$ 1,201,838	$ 1,317,830

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 11, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lease term								5 years 6 months
Base rent		$ 77,357		$ 168,769
Operating expenses		$ 1,792,993	$ 2,190,028	$ 6,152,335	$ 3,096,309	$ 5,996,739	$ 1,058,039
Remaining Lease Term		4 years 8 months 1 day		4 years 8 months 1 day
Operating lease, payments						$ 21,633
Operating Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Base rent	$ 10,817			$ 10,817
Base rent percentage	2.50%			2.50%
Operating expenses	$ 12,000			$ 12,000
Operating lease discount rate	3.95%	3.95%		3.95%		3.95%
Operating lease description	The Company entered into an agreement in December 2020 for approximately 8,500 square feet which is for a five-and-one-half year period.
Operating lease term	P2Y

SCHEDULE OF PROPERTY PLANT & EQ

SCHEDULE OF PROPERTY PLANT & EQUIPMENT (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Total	$ 9,092	$ 9,092
Less: accumulation depreciation	(7,819)	(1,970)
Property and equipment, net	1,273	7,122
Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	701	701
Computer Related [Member]
Property, Plant and Equipment [Line Items]
Total	7,220	7,220
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	$ 1,171	$ 1,171

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT, NET (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation, Depletion and Amortization	$ 1,425	$ 1,313	$ 5,849	$ 1,313
Depreciation expense					$ 1,970

SUMMARY OF INTANGIBLE ASSETS AM

SUMMARY OF INTANGIBLE ASSETS AMORTIZATION EXPENSE (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 46,892,745	$ 42,867,700	$ 28,613,000
Accumulated Amortization	(507,624)	(589,489)
Net Carrying Amount	46,385,121	42,278,211	28,613,000
Krillase Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	28,600,000	28,600,000
Accumulated Amortization
Net Carrying Amount	28,600,000	28,600,000
Dura Graft Patent [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	5,256,000	14,147,729
Accumulated Amortization	(471,691)	(589,489)
Net Carrying Amount	4,784,309	13,558,240
Distributor Relationship [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	308,000
Accumulated Amortization	(35,933)
Net Carrying Amount	272,067
I P R And D Cyto Protectant Life Sciences [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	12,606,000
Accumulated Amortization
Net Carrying Amount	12,606,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	122,745	119,971	13,000
Accumulated Amortization
Net Carrying Amount	$ 122,745	119,971	13,000
Krillase Patents Patent Applications Research And Development Clinical Trials Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount		28,600,000	28,600,000
Accumulated Amortization
Net Carrying Amount		28,600,000	28,600,000
Dura Graft Patents Patent Applications Research And Development Clinical Trials Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount		14,147,729
Accumulated Amortization		(589,489)
Net Carrying Amount		$ 13,558,240

SCHEDULE OF INTANGIBLE ASSETS (

SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2021		Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Begining Balance	$ 42,278,211		$ 28,613,000
Acquired in asset purchase agreement	4,022,271	[1]	14,147,729
Additions	2,775		106,971
Amortization expense	81,864	[1]	(589,489)
Accumulated amortization			(589,489)
Ending Balance	$ 46,385,121		$ 42,278,211
[1]	To account for Somah Transaction measurement period adjustments, the Company restated the Quarterly Report on Form 10-Q for the three and six month ended June 30, 2021, originally filed on August 23, 2021. As a result of the restatement, the value of DuraGraft intangibles purchased with the Somah Transaction increased by $ 4,022,271 898,026

SCHEDULE OF INTANGIBLE ASSETS_2

SCHEDULE OF INTANGIBLE ASSETS (Details) (Parenthetical) - USD ($)	3 Months Ended			6 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of Intangible Assets	$ 108,777	$ 4,022,271	$ 341,270		$ 326,331	$ 341,270	$ 589,489
Amortization of intangibles decreased				$ 898,026

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	Jul. 31, 2020	Sep. 12, 2018	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Amortization expense			$ 108,777	$ 4,022,271	$ 341,270	$ 326,331	$ 341,270	$ 589,489
Legal and filing fees								17,801
Warrant, shares			250,000			250,000
Amortization expense								589,489
Somah [Member]
Finite-Lived Intangible Assets [Line Items]
Number of shares issues at common stock	10,000,000
Warrant, shares	3,000,000
Dura Graft Patent [Member]
Finite-Lived Intangible Assets [Line Items]
Future amortizations for next five years			$ 435,108			$ 435,108		1,414,773
Future amortizations, thereafter			$ 2,880,836			$ 2,880,836		$ 825,284
Krillase Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Issuance of common stock for acquisition, shares		16,980,000
Krillase Technology [Member] | ACB Holding AB [Member]
Finite-Lived Intangible Assets [Line Items]
Issuance of common stock for acquisition, shares		28,600,000

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Trade accounts payable	$ 1,117,517	$ 325,830
Accrued expenses	180,846	21,555
Accrued compensation expenses	98,582	130,718
Total accounts payable and accrued expenses	$ 1,396,945	$ 478,103

SCHEDULE OF CONVERTIBLE NOTES (

SCHEDULE OF CONVERTIBLE NOTES (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Convertible notes issued	$ 1,174,945
Issuance costs	(105,745)
Debt discount	(964,153)
Debt accretion	74,410
Convertible notes, net of debt discount	$ 179,457

CONVERTIBLE PROMISSORY NOTES _3

CONVERTIBLE PROMISSORY NOTES AND WARRANTS (Details Narrative)	Sep. 29, 2021$ / sharesshares	May 31, 2021USD ($)$ / sharesshares	May 27, 2021$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares	Jul. 31, 2021USD ($)shares	May 31, 2021USD ($)$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)
Debt Instrument [Line Items]
Sale of stock shares						29,978
Sale of Stock, Price Per Share | $ / shares		$ 2.50				$ 2.50
Proceeds from Notes Payable | $		$ 74,945
Warrants to purchase common shares				250,000			250,000		250,000
Issuance costs | $		$ 6,745				$ 6,745
Fair Value Adjustment of Warrants | $				$ 2,899,000					$ 571,807
Derivative Assets (Liabilities), at Fair Value, Net | $				$ 391,648			$ 391,648		391,648
Interest and accretion expenses | $							$ 70,221		$ 74,410
Debt instrument conversion price | $ / shares				$ 2.25			$ 2.25		$ 2.25
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Frequency of periodic payment									The Convertible Notes mature in 24 months from the initial closing date and accrue 10% of simple interest per annum on the outstanding principal amount.
Debt Instrument, Interest Rate, Stated Percentage				10.00%			10.00%		10.00%
Debt instrument conversion description									The Convertible Notes principal and accrued interest can be converted at any time at the option of the holder at a conversion price of $2.25 per share (before the modification - $2.50 per share)
Percentage of debt instrument of conversion price									0.75
Maximum [Member]
Debt Instrument [Line Items]
Debt conversion price per share | $ / shares	$ 2.50
Minimum [Member]
Debt Instrument [Line Items]
Debt conversion price per share | $ / shares	2.25
Minimum [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Equity financing gross amount | $				$ 10,000,000			$ 10,000,000		$ 10,000,000
Class A Warrants [Member]
Debt Instrument [Line Items]
Sale of stock amount | $					$ 1,100,000	$ 74,945
Warrants to purchase common shares		29,978				29,978
Percentage of debt instrument of conversion price									0.75
Debt instrument conversion price | $ / shares				$ 2.50			$ 2.50		$ 2.50
Warrants exercise price per share | $ / shares									$ 3.13
Warrants exercisable term									5 years
Percentage of warrant coverage									1
Class B Warrants [Member]
Debt Instrument [Line Items]
Warrants to purchase common shares		29,978				29,978
Warrants exercise price per share | $ / shares									$ 5
Warrants exercisable term									5 years
Percentage of warrant coverage									1
Class C Warrants [Member]
Debt Instrument [Line Items]
Percentage of debt instrument of conversion price									0.75
Debt instrument conversion price | $ / shares				$ 2.25			$ 2.25		$ 2.25
Warrants exercise price per share | $ / shares									$ 2.25
Warrants exercisable term									5 years
Percentage of warrant coverage									2
Unit Purchase Agreement [Member]
Debt Instrument [Line Items]
Sale of stock shares			4,000,000
Sale of Stock, Price Per Share | $ / shares			$ 2.50
Debt description			Each Unit is comprised of (i) a convertible promissory note (the “Convertible Note”) convertible into common stock of the Company at a price per share of $2.50, (ii) a warrant to purchase one share of common stock of the Company (the ‘Class A Warrant’); and (iii) a second warrant to purchase common stock of the Company (the “Class B Warrant”).
Pro rata units				469,978			469,978		469,978
Aggregate pro rata units				522,198			522,198		522,198
Unit Purchase Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Sale of Stock, Price Per Share | $ / shares	2.50
Unit Purchase Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Sale of Stock, Price Per Share | $ / shares	$ 2.25
Unit Purchase Agreement [Member] | Class A Warrants [Member]
Debt Instrument [Line Items]
Warrants to purchase common shares			29,978		440,000
Warrants exercisable term									5 years
Unit Purchase Agreement [Member] | Class B Warrants [Member]
Debt Instrument [Line Items]
Warrants to purchase common shares			29,978		440,000
Warrants exercisable term									5 years
Unit Purchase Agreement [Member] | Class C Warrants [Member]
Debt Instrument [Line Items]
Aggregate pro rata units	1,044,396
Warrants exercisable term									5 years
Unit Purchase Program [Member]
Debt Instrument [Line Items]
Sale of stock shares					440,000
Proceeds from Notes Payable | $					$ 1,100,000
Issuance costs | $					$ 99,000
Unit Purchase Program [Member] | Class A Warrants [Member]
Debt Instrument [Line Items]
Warrants to purchase common shares					440,000
Unit Purchase Program [Member] | Class B Warrants [Member]
Debt Instrument [Line Items]
Warrants to purchase common shares					440,000

SCHEDULE OF SHARE BASED STOCK O

SCHEDULE OF SHARE BASED STOCK OPTION VALUATION ASSUMPTIONS (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Equity [Abstract]
Risk-free interest rate	0.69%	0.93%
Volatility	232.69%	241.88%
Exercise price	$ 1.25	$ 1.37
Dividend yield	0.00%	0.00%
Forfeiture rate	0.00%	0.00%
Expected life (years)	3 years	10 years

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Number of Options, Outstanding Ending Balance	3,800,943	2,715,000	265,000
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 1.36	$ 1.50	$ 1.50
Weighted average contractual life term, outstanding		9 years 5 months 23 days
Number of Options, Granted	732,500	1,340,000	2,450,000
Weighted Average Exercise Price, Granted	$ 1.25	$ 1.25	$ 1.01
Number of Options, Exercised		(254,057)
Weighted Average Exercise Price, Exercised		$ 1.02
Weighted Average Contractual Term, Outstanding Ending Balance	8 years 1 month 17 days	8 years 9 months 25 days
Total Intrinsic Value, Beginning Balance	$ 123,600
Number of Options, Forfeited	(760,626)
Weighted Average Exercise Price, Forfeited	$ 1.25
Number of Options, Outstanding Ending Balance	3,772,817	3,800,943	2,715,000
Weighted Average Exercise Price, Outstanding Ending Balance	$ 1.37	$ 1.36	$ 1.50
Total Intrinsic Value, Ending Balance	$ 97,850	$ 123,600
Number of Options, Exercisable	3,074,476	2,755,110
Weighted Average Exercise Price, Exercisable	$ 1.39	$ 1.40
Weighted average contractual life term, exercisable	3 years 9 months 7 days
Total Intrinsic Value, exercisable	$ 97,850
Number of Options, Exercised		254,057
Number of Options, Forfeited	760,626
Total Intrinsic Value, Ending Balance	$ 97,850	$ 123,600

SCHEDULE OF OPTIONS OUTSTANDING

SCHEDULE OF OPTIONS OUTSTANDING AND EXERCISABLE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Sep. 30, 2021	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	3,800,943	3,772,817	2,715,000	265,000
Number of Options Exercisable	2,755,110	3,074,476
Intrinsic value	$ 123,600	$ 97,850
Exercise Price Range at 1.01 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 1.01
Number of Options Outstanding	515,000
Number of Options Exercisable	515,000
Term	10
Intrinsic value	$ 123,600
Exercise Price Range at 1.01 [Member] | Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Remaining Life in Years	7 years 11 months 4 days
Exercise Price Range at 1.01 [Member] | Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Remaining Life in Years	8 years 10 days
Exercise Price Range at 1.25 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 1.25
Number of Options Outstanding	890,000
Number of Options Exercisable	14,167
Term	10
Intrinsic value
Exercise Price Range at 1.25 [Member] | Minimum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Remaining Life in Years	9 years 9 months 21 days
Exercise Price Range at 1.25 [Member] | Maximum [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Remaining Life in Years	9 years 11 months 1 day
Exercise Price Range at 1.37 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 1.37
Number of Options Outstanding	200,000
Number of Options Exercisable	30,000
Term	10
Remaining Life in Years	9 years 7 months 17 days
Intrinsic value
Exercise Price Range at 1.50 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price	$ 1.50
Number of Options Outstanding	2,195,943
Number of Options Exercisable	2,195,943
Term	10
Remaining Life in Years	8 years 6 months 10 days
Intrinsic value

SCHEDULE OF OPTIONS OUTSTANDI_2

SCHEDULE OF OPTIONS OUTSTANDING AND ISSUED (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock options outstanding, Begining balance	3,393,651
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 1.36	$ 1.50
Stock options outstanding, Ending balance		3,393,651
Weighted Average Exercise Price, Outstanding Ending Balance	$ 1.37	$ 1.36
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock options outstanding, Begining balance	3,393,651	113,637
Weighted Average Exercise Price, Outstanding Beginning Balance		$ 3
Stock options outstanding, issued	$ 1,044,396	$ 280,014
Weighted average exercise price, issued	$ 2.25	$ 1.38
Weighted average exercise price, outstanding	$ 2.13
Stock options outstanding, Ending balance	4,438,047	3,393,651
Weighted Average Exercise Price, Outstanding Ending Balance	$ 2.16
Warrant [Member] | Somah Acquisition [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock options outstanding, issued		$ 3,000,000
Weighted average exercise price, issued		$ 5

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	May 27, 2021	Jan. 13, 2021	Dec. 01, 2020	Nov. 09, 2020	Nov. 01, 2020	Oct. 30, 2020	Oct. 22, 2020	Sep. 25, 2020	Sep. 01, 2020	Aug. 18, 2020	Aug. 03, 2020	Aug. 02, 2020	Jul. 31, 2020	Jul. 28, 2020	Jul. 28, 2020	Jun. 08, 2020	Apr. 06, 2020	Jan. 09, 2020	Jun. 12, 2019	May 31, 2021	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Sep. 29, 2021	Jul. 31, 2021	Oct. 01, 2020
Class of Warrant or Right [Line Items]
Preferred stock, shares authorized																					25,000,000				25,000,000		25,000,000	25,000,000
Preferred stock, par value per share																					$ 0.001				$ 0.001		$ 0.001	$ 0.001
Preferred stock, shares issued																					0				0		0	0
Preferred stock, shares outstanding																					0				0		0	0
Common stock, shares authorized																					75,000,000				75,000,000		75,000,000	75,000,000
Common stock, par value per share																					$ 0.001				$ 0.001		$ 0.001	$ 0.001
Common stock, shares, issued																					35,928,188				35,928,188		35,928,188	19,858,939
Common stock, shares, outstanding																					35,928,188				35,928,188		35,928,188	19,858,939
Stock issued for exercised of options																											254,057
Stock option granted																									732,500		1,340,000	2,450,000
Warrant to purchase shares of common stock																					250,000				250,000
Share-based Payment Arrangement, Noncash Expense																					$ 64,074				$ 593,116	$ 1,420,451	$ 1,329,643	$ 698,587
[custom:NonCashShareBasedCompensation]																									1,107,085	1,674,200
Restricted Stock or Unit Expense																									33,333
Unrecognized stock based compensation																									$ 652,932
Unrecognized stock based Compensation weighted average contract period																									2 years 5 months 8 days
Stock issued during the period																						$ 6,275,064						125,000
Stock issued during the period for services rendered																						$ 62,500		$ 125,000			237,500
Issuance of common stock in lieu of conversion of debt																							$ 184,860				261,453
Sale of common stock to accredited investors																				29,978
Share issued price per share																				$ 2.50
Advisory fees																											17,801
Proceeds from issuance of common stock																										$ 6,275,064	$ 6,275,164	$ 125,000
Stock option exercise price per share																					$ 1.39				$ 1.39		$ 1.40
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term																									3 years		10 years
Expected volatility rate minimum																											179.31%
Expected volatility rate maximum																											304.44%
Expected dividends rate																									0.00%		0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate																									0.69%		0.93%
Unamortized amount of stock option																											$ 1,237,167
Weighted average grant date fair value of options granted																									$ 1.25		$ 1.25	$ 1.01
Warrants outstanding																											3,393,651
Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise price																											$ 1.01
Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise price																											$ 1.37
Consultant [Member]
Class of Warrant or Right [Line Items]
Stock based compensation expenses																											$ 222,385
Share based payment award, fair value																											$ 1.01
Placement Agent [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Warrant to purchase shares of common stock												229,499
Warrant exercise price per share												$ 1.375
Sale of stock, description												In consideration for services rendered as the placement agent in the Private Placement, on August 2, 2020, the Company paid Univest Securities LLC cash commissions totaling $460,999, or 8% of the gross proceeds of the Private Placement closing, a 1% non-accountable expense allowance totaling $57,625, and the $31,250 balance (of a total of $37,500) due to the placement agent in advisory fees.
Commissions paid to placement agent for services rendered												$ 460,999
Non-accountable expenses allowance paid to placement agent												57,625
Advisory fees												31,250
Proceeds from warrant exercises												$ 100
Common Stock [Member]
Class of Warrant or Right [Line Items]
Stock issued for exercised of options																						54,057	5,000
Warrant to purchase shares of common stock																			113,637
Warrant exercise price per share																			$ 3
Issuance of common stock for acquisition, shares																						10,000,000					10,000,000
Stock issued during the period																						$ 5,600						$ 119
Stock issued during the period for services rendered, shares																						50,000		125,000			215,000
Stock issued during the period for services rendered																						$ 50		$ 125			$ 215
Issuance of common stock in lieu of conversion of debt, shares															64,057								195,000				254,057
Issuance of common stock in lieu of conversion of debt															$ 59,453								$ 195				$ 254
Stock issued during the period, shares																						5,600,192						118,637
Common Stock [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Class of Warrant or Right [Line Items]
Issuance of common stock in lieu of conversion of debt, shares								990,208
Gross amount received from second tranche of funding								$ 1,237,760
Net amount received from second tranche of funding								$ 1,116,566
Common Stock [Member] | Consultant [Member]
Class of Warrant or Right [Line Items]
Stock issued for exercised of options																20,000	160,000	125,000
Stock option granted																		250,000
Issuance of common stock in lieu of accounts payable																$ 20,200	$ 161,600	$ 126,250
Stock issued during the period														$ 25,000
Stock issued during the period for services rendered, shares																	15,000
Stock issued during the period for services rendered																	$ 15,150
Stock issued during the period, shares														20,000
Stock option exercise price per share																		$ 1.01
Stock option expiration period																		10 years
Remaining stock option vest per month at grant																		25,000
Common Stock [Member] | Director [Member]
Class of Warrant or Right [Line Items]
Stock issued for exercised of options																	5,000
Stock issued during the period																	$ 5,050
Common Stock [Member] | Accredited Investors [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Sale of common stock to accredited investors											4,609,984
Share issued price per share											$ 1.25
Common Stock [Member] | Chief Financial Officer [Member]
Class of Warrant or Right [Line Items]
Stock option granted							120,000
Stock-based payment award vesting period							3 years
Stock option exercise price per share							$ 1.25
Stock option expiration period							10 years
Stock based compensation expenses																											6,250
Share based payment award, fair value							$ 1.2453
Unamortized amount of stock option																											143,210
Share based payment award, description							On March 5, 2021, the Company accelerated the vesting to 50% as of this date and the remaining 50% as of October 22, 2021 (see Note 12
Common Stock [Member] | Consultant One [Member].
Class of Warrant or Right [Line Items]
Stock option granted										200,000
Stock-based payment award vesting period										18 months
Stock option exercise price per share										$ 1.37
Stock option expiration period										10 years
Stock based compensation expenses																											$ 66,024
Share based payment award, fair value																											$ 1.25
Unamortized amount of stock option																											$ 175,000
Common Stock [Member] | Employee [Member].
Class of Warrant or Right [Line Items]
Stock option granted							50,000
Stock-based payment award vesting period							3 years
Stock option exercise price per share							$ 1.25
Stock option expiration period							10 years
Stock based compensation expenses																											2,604
Unamortized amount of stock option																											59,671
Common Stock [Member] | Consultant Two [Member].
Class of Warrant or Right [Line Items]
Stock option granted						125,000
Stock-based payment award vesting period						3 years
Stock option exercise price per share						$ 1.25
Stock option expiration period						10 years
Stock based compensation expenses																											6,510
Share based payment award, fair value						$ 1.2454
Unamortized amount of stock option																											149,189
Common Stock [Member] | Dr.Neil J. Campbell [Member]
Class of Warrant or Right [Line Items]
Stock option granted					500,000
Stock-based payment award vesting period					3 years
Stock option exercise price per share					$ 1.25
Stock option expiration period					10 years
Stock based compensation expenses																											26,042
Share based payment award, fair value					$ 1.2454
Unamortized amount of stock option																											596,754
Common Stock [Member] | Employee One [Member]
Class of Warrant or Right [Line Items]
Stock option granted				15,000
Stock-based payment award vesting period				3 years
Stock option exercise price per share				$ 1.25
Stock option expiration period				10 years
Stock based compensation expenses																											868
Share based payment award, fair value				$ 1.2445
Unamortized amount of stock option																											17,806
Common Stock [Member] | Dr. Steven Brooks, CMO [Member]
Class of Warrant or Right [Line Items]
Stock option granted			40,000
Stock-based payment award vesting period			3 years
Stock option exercise price per share			$ 1.25
Stock option expiration period			10 years
Stock based compensation expenses																											1,330
Share based payment award, fair value			$ 1.2462
Unamortized amount of stock option																											47,771
Common Stock [Member] | Executive Vice President [Member]
Class of Warrant or Right [Line Items]
Stock based compensation expenses																											2,083
Unamortized amount of stock option																											$ 47,767
Common Stock [Member] | Somahlution Inc [Member]
Class of Warrant or Right [Line Items]
Issuance of common stock for acquisition, shares													10,000,000
Fair market value of warrant per share													$ 0.6441
Fair market value of warrant													$ 1,932,300
Fair value of common stock and warrants													$ 12,500,000
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding																					4,438,047				4,438,047		3,393,651	113,637
Warrant [Member] | Somahlution Inc [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share													$ 5
Issuance of common stock for acquisition, shares													3,000,000
Fair market value of warrant per share													$ 0.40
Fair market value of warrant													$ 1,200,000
Fair value of common stock and warrants													$ 1,932,300
Warrant One [Member]
Class of Warrant or Right [Line Items]
Warrant to purchase shares of common stock								168,008
Warrant exercise price per share								$ 1.375
Warrant term								5 years
Fair market value of warrant per share								$ 0.9062
Fair market value of warrant								$ 152,249
Warrant One [Member] | Somahlution Inc [Member]
Class of Warrant or Right [Line Items]
Warrant term								5 years
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Warrant to purchase shares of common stock								112,006
Warrant exercise price per share								$ 1.375
Warrant term								5 years
Fair market value of warrant per share								$ 0.9062
Fair market value of warrant								$ 101,500
Warrant One and Two [Member]
Class of Warrant or Right [Line Items]
Fair market value of warrant								$ 253,749
Common Stock One [Member]
Class of Warrant or Right [Line Items]
Stock issued during the period																			$ 90,910
Share issued price per share																			$ 1.10
Stock-based payment award vesting period																			3 years
Proceeds from issuance of common stock																			$ 100,000
Stock option exercise price per share																			$ 3
Common Stock Two [Member]
Class of Warrant or Right [Line Items]
Stock issued during the period																			$ 27,727
Share issued price per share																			$ 0.9016
Proceeds from issuance of common stock																			$ 25,000
Unit Purchase Agreement [Member]
Class of Warrant or Right [Line Items]
[custom:AggregateProRataUnits-0]																					522,198				522,198
Sale of common stock to accredited investors	4,000,000
Share issued price per share	$ 2.50
Unit Purchase Agreement [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Share issued price per share																													$ 2.25
Unit Purchase Agreement [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Share issued price per share																													2.50
Consulting Agreement [Member]
Class of Warrant or Right [Line Items]
Warrant to purchase shares of common stock																															36,364
Warrant exercise price per share																															$ 1.375
Consulting Agreement [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Share issued price per share																															$ 1.25
Class A Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant to purchase shares of common stock																				29,978
Warrants exercisable term																									5 years
Class A Warrants [Member] | Unit Purchase Agreement [Member]
Class of Warrant or Right [Line Items]
Warrant to purchase shares of common stock	29,978																													440,000
Warrant exercise price per share	$ 3.13
Warrants exercisable term																									5 years
Class B Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant to purchase shares of common stock																				29,978
Warrants exercisable term																									5 years
Class B Warrants [Member] | Unit Purchase Agreement [Member]
Class of Warrant or Right [Line Items]
Warrant to purchase shares of common stock	29,978																													440,000
Warrant exercise price per share	$ 5
Warrants exercisable term																									5 years
Class C Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants exercisable term																									5 years
Class C Warrants [Member] | Unit Purchase Agreement [Member]
Class of Warrant or Right [Line Items]
Warrant exercise price per share																													$ 2.25
Warrants exercisable term																									5 years
[custom:AggregateProRataUnits-0]																													1,044,396
Stock Incentive Plan [Member]
Class of Warrant or Right [Line Items]
Stock issued for exercised of options		5,300,000																							1,527,183
Restricted Stock [Member]
Class of Warrant or Right [Line Items]
Warrant to purchase shares of common stock																					3,000,000				3,000,000
Warrant exercise price per share																					$ 5				$ 5
Warrant term																					5 years				5 years
Stock issued during the period for services rendered, shares																									10,000,000
Restricted Stock [Member] | Chief Financial Officer [Member]
Class of Warrant or Right [Line Items]
Restricted shares of common stock issued									40,000
Stock-based payment award vesting period									1 year

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Related Party Transactions [Abstract]
Related party transactions owned	$ 638,530		$ 638,530
Proceeds from related party	151,000
Proceeds from related party and shareholders debt			215,000
Related party transactions, professional expenses	30,000	$ 90,000	270,000	$ 90,000
Related party transactions, administrative and general expenses			2,530
Related party transaction			272,530
Prepaid royalties	$ 340,969		$ 340,969		$ 344,321

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Nov. 01, 2020	Oct. 22, 2020	Sep. 01, 2020	Jul. 13, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Salary and wage					$ 617,826	$ 433,318	$ 2,478,357	$ 433,318	$ 1,153,978
Issuance of stock options							732,500		1,340,000	2,450,000
Royalties percentage							10.00%		10.00%
Leasing for office space									$ 10,701
Vesting period							8 years 1 month 17 days		8 years 9 months 25 days
Exercise price per share					$ 1.39		$ 1.39		$ 1.40
Employment And Consulting Agreements [Member] | Chief Financial Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of stock options		120,000	40,000
Compensation			$ 120,000
Vesting period		3 years	1 year
Exercise price per share		$ 1.25
Employment And Consulting Agreements [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of stock options	500,000
Compensation	$ 375,000
Vesting period	3 years
Exercise price per share	$ 1.25
UNITED STATES | First Fifty Million [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Royalties percentage							5.00%		5.00%
UNITED STATES | Fifty Million Up To Two Hundred Million [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Royalties percentage							4.00%		4.00%
UNITED STATES | Over Two Hundred Million [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Royalties percentage							2.00%		2.00%
Non-US [Member] | First Fifty Million [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Royalties percentage							6.00%		6.00%
Non-US [Member] | Fifty Million Up To Two Hundred Million [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Royalties percentage							4.00%		4.00%
Non-US [Member] | Over Two Hundred Million [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Royalties percentage							2.00%		2.00%
July Thirteen Two Thousandand Twenty Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Salary and wage				$ 30,000
Issuance of stock options				250,000
July Thirteen Two Thousand and Twenty One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of stock options				250,000
Shares issued, price per share				$ 1.50

SUBSEQUENT EVENT (Details Narra

SUBSEQUENT EVENT (Details Narrative) - $ / shares	Mar. 05, 2021	Jan. 31, 2021	Jan. 29, 2021	Jan. 16, 2021	Jan. 12, 2021	Jan. 02, 2021	Oct. 22, 2020	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Nov. 01, 2021
Subsequent Event [Line Items]
Stock option granted								732,500	1,340,000	2,450,000
Stock option exercise price per share								$ 1.39	$ 1.40
Common Stock [Member] | Employee [Member].
Subsequent Event [Line Items]
Stock option granted							50,000
Stock-based payment award vesting period							3 years
Stock option exercise price per share							$ 1.25
Stock option expiration period							10 years
Subsequent Event [Member]
Subsequent Event [Line Items]
Aggregate common stock shares issued											4,600,000
Share based payment award, description	On March 5, 2021, the Company modified the vesting of the common stock and stock options issued to Mr. Harmon. As of this date, all common stock was vested and 50% of the stock options were vested as of this date and the remaining 50% vest on October 22, 2021. See Note 10.
Subsequent Event [Member] | Employee [Member].
Subsequent Event [Line Items]
Stock option vested at grant		50,000
Subsequent Event [Member] | Common Stock [Member] | Employee [Member].
Subsequent Event [Line Items]
Stock option granted					20,000	7,500
Stock-based payment award vesting period					3 years	3 years
Stock option exercise price per share					$ 1.25	$ 1.25
Stock option expiration period					10 years	10 years
Subsequent Event [Member] | Common Stock [Member] | Executive Vice President [Member]
Subsequent Event [Line Items]
Stock option granted				40,000
Stock-based payment award vesting period				3 years
Stock option exercise price per share				$ 1.25
Stock option expiration period				10 years
Subsequent Event [Member] | Common Stock [Member] | Amy Chandler, Executive Vice President [Member].
Subsequent Event [Line Items]
Stock option granted			40,000
Stock-based payment award vesting period			3 years
Stock option exercise price per share			$ 1.25
Stock option expiration period			10 years
Subsequent Event [Member] | Common Stock [Member] | Board of Directors Chairman [Member]
Subsequent Event [Line Items]
Stock option granted	125,000
Stock-based payment award vesting period	3 years
Stock option exercise price per share	$ 1.25
Stock option expiration period	10 years
Subsequent Event [Member] | Common Stock [Member] | Director [Member]
Subsequent Event [Line Items]
Stock option granted	125,000
Stock-based payment award vesting period	3 years
Stock option exercise price per share	$ 1.25
Stock option expiration period	10 years
Subsequent Event [Member] | Common Stock [Member] | Dr. William Hearl, Director [Member]
Subsequent Event [Line Items]
Stock option granted	125,000
Stock-based payment award vesting period	3 years
Stock option exercise price per share	$ 1.25
Stock option expiration period	10 years
Subsequent Event [Member] | Common Stock [Member] | Julie Kamof, Director [Member]
Subsequent Event [Line Items]
Stock option granted	125,000
Stock-based payment award vesting period	3 years
Stock option exercise price per share	$ 1.25
Stock option expiration period	10 years
Subsequent Event [Member] | Common Stock [Member] | Dr. Vithal Dhaduk, Director [Member]
Subsequent Event [Line Items]
Stock option granted	125,000
Stock-based payment award vesting period	3 years
Stock option exercise price per share	$ 1.25
Stock option expiration period	10 years

ORGANIZATION AND DESCRIPTION _2

ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative) - $ / shares shares in Thousands	Sep. 12, 2018	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Jun. 01, 2018
Common stock, par value		$ 0.001	$ 0.001	$ 0.001
Krillase Technology [Member]
Issuance of common stock for acquisition, shares	16,980
X- Assets Enterprises, Inc [Member]
Equity ownership method, percentage					100.00%

SCHEDULE OF INCOME TAX EXPENSE

SCHEDULE OF INCOME TAX EXPENSE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Tax expense (benefit) at the statutory rate	$ (1,158,482)	$ (222,188)
Non-deductible items	385,216
Deferred true-ups	(56,746)
Change in valuation allowance	830,012	222,188
Total

SCHEDULE OF EFFECTIVE INCOME TA

SCHEDULE OF EFFECTIVE INCOME TAX RATES (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
U.S. statutory federal rate	21.00%	21.00%
Non-deductible / non-taxable items	(6.50%)	0.00%
Deferred true-up	(1.00%)	0.00%
Valuation allowance	(13.50%)	(21.00%)
Total provision	0.00%	0.00%

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$ 6,504,000	$ 5,785,000
Lease liability	277,000
Intangible assets	181,000
Fixed assets	(277,000)
Total gross deferred tax assets	6,685,000	5,785,000
Less: Deferred tax asset valuation allowance	(6,685,000)	(5,785,000)
Total net deferred taxes

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 30,973,000	$ 27,552,000
Deferred tax assets, valuation allowance	$ 6,685,000	$ 5,785,000